university of groningen

## University of Groningen

Single-Cell RNA Sequencing of Blood and Ileal T Cells From Patients With Crohn's Disease Reveals Tissue-Specific Characteristics and Drug Targets<br>Uniken Venema, Werna T; Voskuil, Michiel D; Vich Vila, Arnau; van der Vries, Gerben;<br>Jansen, Bernadien H; Jabri, B; Faber, Klaas Nico; Dijkstra, Gerard; Xavier, Ramnik J; Wijmenga, Cisca<br>Published in:<br>Gastroenterology

DOI:
10.1053/j.gastro.2018.10.046

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Final author's version (accepted by publisher, after peer review)

Publication date:
2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Uniken Venema, W. T., Voskuil, M. D., Vich Vila, A., van der Vries, G., Jansen, B. H., Jabri, B., Faber, K. N., Dijkstra, G., Xavier, R. J., Wijmenga, C., Graham, D. B., Weersma, R. K., \& Festen, E. A. (2019). Single-Cell RNA Sequencing of Blood and Ileal T Cells From Patients With Crohn's Disease Reveals Tissue-Specific Characteristics and Drug Targets. Gastroenterology, 156(3), 812-+. https://doi.org/10.1053/j.gastro.2018.10.046

## Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

[^0]
## Accepted Manuscript

Single-cell RNA Sequencing of Blood and Ileal T cells From Patients With Crohn's Disease Reveals Tissue-specific Characteristics and Drug Targets<br>Werna T. Uniken Venema, Michiel D. Voskuil, Arnau Vich Vila, Gerben van der Vries, Bernadien H. Jansen, B. Jabri, Klaas Nico Faber, Gerard Dijkstra, Ramnik J. Xavier, Cisca Wijmenga, Daniel B. Graham, Rinse K. Weersma, Eleonora A. Festen A Controlled Trial

of fluten-Free Difet of Gluten-Free Diet

| PII: | S0016-5085(18)35203-X |
| :--- | :--- |
| DOI: | https://doi.org/10.1053/j.gastro.2018.10.046 |
| Reference: | YGAST 62225 |

To appear in: Gastroenterology
Accepted Date: 27 October 2018

Please cite this article as: Uniken Venema WT, Voskuil MD, Vich Vila A, van der Vries G, Jansen BH, Jabri B, Faber KN, Dijkstra G, Xavier RJ, Wijmenga C, Graham DB, Weersma RK, Festen EA, Single-cell RNA Sequencing of Blood and Ileal T cells From Patients With Crohn's Disease Reveals Tissue-specific Characteristics and Drug Targets, Gastroenterology (2018), doi: https://doi.org/10.1053/ j.gastro.2018.10.046.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Title:

Single-cell RNA Sequencing of Blood and Ileal T cells From Patients With Crohn's Disease Reveals Tissue-specific Characteristics and Drug Targets

## Short title:

scRNA sequencing of T cells in Crohn's disease

## Authors:

Uniken Venema, Werna T. ${ }^{1, *}$; Voskuil, Michiel D. ${ }^{1, *}$; Vich Vila, Arnau ${ }^{1,2}$; van der Vries, Gerben ${ }^{2}$; Jansen, Bernadien H. ${ }^{1}$; B. Jabri ${ }^{3}$; Faber, Klaas Nico ${ }^{1,4}$; Dijkstra, Gerard ${ }^{1}$; Xavier, Ramnik J. ${ }^{5,6}$; Wijmenga, Cisca²; Graham, Daniel B. ${ }^{5,6}$; Weersma, Rinse K. ${ }^{1}$; Festen, Eleonora A. ${ }^{1,2}$

## Institutions:

1) Dept. of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 2) Dept. of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 3) Department of Medicine and Committee on Immunology, University of Chicago, Chicago, IL, USA 4) Dept. of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 5) Broad Institute of Harvard and MIT, Cambridge, MA, USA; 6) Division of Gastroenterology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

* Shared first authors


## Grant support:

C. Wijmenga is supported by a European Research Council (ERC) advanced grant (FP/20072013/ERC grant 2012-322698), a Netherlands Organization for Scientific Research (NWO) Spinoza prize (NWO SPI 92-266), the NWO Gravitation Netherlands Organ-on-Chip Initiative (O24.003.001), the Stiftelsen Kristian Gerhard Jebsen foundation (Norway) and a RuG investment agenda grant Personalized Health. R.K. Weersma is supported by an NWO VIDI grant (016.136.308). E.A.M. Festen is supported by a Dutch Digestive Foundation Career Development grant (CDG 14-04). W.T.C. Uniken Venema is supported by the Foundation "De

Drie Lichten", the Netherlands, and the Boehringer Ingelheim Fonds. The Department of Genetics, Section Research and Development, University of Groningen, University Medical Center Groningen contributed to laboratory expenses for this study.

## Statement of author contributions:

W.T.C.U.V. and M.D.V contributed equally to this work and are shared first authors. W.T.C.U.V. and M.D.V and E.A.M.F. participated in conception, design and coordination of the study. G.D., R.K.W. and E.A.M.F recruited patients. W.T.C.U.V., M.D.V. and B.H.J. performed the laboratory experiments. W.T.C.U.V., M.D.V., G.v.d.V., A.V.V and E.A.M.F. performed the data analyses and data interpretation. B.J., K.N.F., G.D., R.J.X., C.W. and D.B.G. provided support with data interpretation. All authors assisted in the writing and reviewing of the manuscript, and approved of sending it out for publication.

## Abbreviations:

| CD | Crohn's disease |
| :--- | :--- |
| CTL | Cytotoxic T lymphocytes |
| IEL | Intraepithelial T lymphocytes |
| LPL | Lamina propria T lymphocytes |
| PBL | Peripheral blood T lymphocytes |
| SCRNAseq | Single-cell RNA (ribonucleic acid) sequencing |
| Th17 | T-helper 17 |
| Treg | T-regulatory cell |

## Corresponding author:

E.A.M. Festen, MD, PhD, Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, PO Box 30001, Hanzeplein 1, 9700 RB Groningen, the Netherlands, e.a.m.festen@umcg.nl

## Conflict of interests statement:

There are no (potential) conflicts of interest to declare.

## Writing assistance:

This article was edited for language and formatting by Kate Mc Intyre, Scientific Editor in the Department of Genetics, University Medical Center Groningen.

## Acknowledgements:

The authors thank the patients-participants of the 1000IBD cohort for contributing blood and intestinal biopsies; Dianne Jansen, Tjasso Blokzijl, Desiree Brandenbrug-Weening, Jelkje de Boer, Kim de Lange, Tim Raine and Pieter van der Vlies for laboratory support; Patricia Rogers, Wayel Abdulahad and Geert Mesander for technical assistance with fluorescence-activated cell sorting; Rudi Alberts for data management support; the UMCG Genomics Coordination center, the UG Center for Information Technology and their sponsors BBMRI-NL \& TarGet for storage and computer infrastructure; and Timothy Tickle and Mark Daly for contributing to the scientific discussion.

## Introduction:

Crohn's disease (CD) is a chronic inflammatory disease predominantly affecting the terminal ileum. The $\sim 200$ CD-risk loci identified by genome-wide association studies (GWAS) are enriched for genes involved in T-cell signalling, highlighting the importance of $T$ cells in CD pathology ${ }^{1,2}$. It is crucial to study T cells in their disease-relevant context: the intestinal mucosa. Although human single-cell atlases are in development ${ }^{3}$, location- and disease-specific singlecell RNA sequencing (scRNAseq) datasets are still scarce. Here we use scRNAseq of diseaserelevant cells to examine pathomechanisms and identify potential drug targets on a cellular level in CD.

## Methods:

We performed flow-cytometry and scRNAseq of 5,292 CD3-positive T cells isolated from peripheral blood (PBL) and ileal biopsies of three CD patients with mild to moderate disease activity (Figure 1, step 1). Biopsies were dissociated and separated into intraepithelial T lymphocytes (IEL) and lamina propria $T$ lymphocytes (LPL) ${ }^{4}$. We then integrated T-cell transcriptomes with GWAS CD-risk loci and drug-target identification resources. Through literature search and online database analysis, we identified 179 CD-risk genes and 2,712 drugtarget genes that we aligned to differentially expressed genes. Finally, we selected genes encoding proteins targeted by drugs currently available for (clinical trials in) humans (Supplementary Methods).

## Results:

After quality control, 4,070 T cells remained for analysis. These cells expressed 966 genes per cell, on average, and 41,134 distinct genes in total (Figure 1, step 2). IEL, LPL and PBL showed markedly different expression profiles (Supplementary Figure 1, Supplementary Table 1).

Unsupervised clustering of scRNAseq data identified 6 distinct T-cell types that have different distributions in IEL, LPL and PBL: cytotoxic T lymphocytes (CTL) dominate the IEL, quiescent T cells dominate the PBL reservoir, and T-helper 17 (Th17) cells dominate the LPL (Figure 1, step 3). In peripheral blood, Treg cells intermixed with effector T cells (Effector/Treg cells) and
quiescent T cells (Treg/Quiescent cells). Treg/Quiescent cells were also present in the IEL and LPL. In both the IEL and LPL, we identified a cluster of cells of a previously undefined cell type characterized by expression of both CD3 and REG1A/B, and confirmed this with immunofluorescence staining. All T-cell subtypes were present in all patients.

Strikingly, all cell-subtype clusters consisted of both epitopic CD8 $\alpha \beta$-positive and -negative cells. Moreover, CD8A and CD8B transcripts were expressed in both epitopic CD8 $\alpha \beta$-positive and -negative cells, which was confirmed in a publicly available naïve CD4+ T-cell scRNAseq dataset ${ }^{5}$.

Using permutation analysis, we found that both IEL and LPL expressed significantly more CD-risk genes than expected by chance ( $P=0.00389$ and $P<0.00001$, respectively), suggesting that cells within these compartments play a role in CD inflammation ${ }^{2}$. PBL were not enriched for CD-riskgene expression ( $P=0.45954$ ). Th17 cells show the highest number of overexpressed CD-risk genes and are most specifically enriched for CD-risk-gene expression ( $P<0.00001$ ). Mucosal CTL and Treg/Quiescent and peripheral blood Effector/Treg cells are also significantly enriched for CD-risk-gene expression ( $P=0.0278, P=0.02477$ and $P=0.00081$, respectively).

We investigated which drug targets are expressed by Th17 and CTL, both cell types with wellcharacterized expression signatures that play a central role in CD pathogenesis (Table 1). Th17 cells showed upregulation of IL17A, whose gene product is targeted by Secukinumab. ITGAE, whose gene product is targeted by Etrolizumab, is upregulated in mucosal CTL. S1PR5, upregulated in peripheral blood CTL, is a known drug target for Ozanimod. Potential targets for drug repositioning include: PDE4D in mucosal Th17 cells, a target for Apremilast, under investigation for treatment of ulcerative colitis; ITGB2 in peripheral blood CTL, a target for Lifitegrast, approved for keratoconjunctivitis sicca; and ALOX5AP in mucosal CTL, a target for Fiboflapon, under investigation for asthma.

## Discussion:

We have demonstrated that multiple ileal mucosal T-cell subtypes and one peripheral blood Tcell subtype from CD patients are enriched for CD-risk-gene expression. T-cell subtypes known to be involved in CD pathogenesis provide promising targets for future cell-type-specific therapies in CD patients. A limitation of our study is the small sample size, which may reduce the amount of variation covered. However, most cell-type-specific gene-expression signatures remained after correcting for inter-individual differences. As location- and disease-specific scRNAseq data are still limited, detailed datasets like ours are an important reference for furthering our understanding of the molecular processes leading to health and disease and identifying potential targets for drug development.

## References:

1. Liu JZ, van Sommeren S, et al. Nat Genet 2015;47:979-986.
2. Farh KK-H, Marson A, et al. Nature 2015;518:337-43.
3. Regev A, et al. Elife 2017;6;e27041
4. Raine T , et al. Gut 2015;64:250-259.
5. Zheng GXY, et al. Nat Commun 2017;8:14049.

Author names in bold designate shared co-first authorship.

## Figure Legends:

Figure 1: Experimental flow chart. EDTA and collagenase are treatments used to isolate intraepithelial and lamina propria cells, respectively. T-cell-subtype characterization as described in Supplementary Methods. In brackets: number of epitopic CD8 $\alpha \beta$-positive T cells measured by flow-cytometry. IEL: intraepithelial T lymphocyte. LPL: lamina propria T lymphocyte. PBL: peripheral blood T lymphocyte. FACS: fluorescence-activated cell sorting.

Table 1: Overexpression of CD-risk genes and genes encoding potential drug targets in ileal mucosal Th17 cells and cytotoxic T lymphocytes

|  | mucosal Th17 cells |  | peripheral blood CTL |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Gene | Function | Gene | Function | Gene | Function |
| CD-risk gene | CCL2O <br> DNAJB4 <br> IFNG <br> IRF4 <br> MAP3K8 | Chemoattractant for various immune cells <br> Heat shock protein, involved in protein folding <br> Cytokine, involved in adaptive/innate immunity <br> Regulation of mucosal Th17 cell differentiation <br> T-helper cell differentiation and IFN $\gamma$ expression | CTSW <br> LSP1 <br> PRKCB <br> PTPRC | Regulation of T cell cytolytic activity <br> Adhesion and trans endothelial migration <br> Apoptosis regulation <br> T cell antigen receptor signaling regulation | PLCG2 <br> PTPN22 <br> SOCS1 | Transmembrane signaling of immune system receptors <br> Negative regulator of TCR signaling, positive regulator of TLR signaling <br> Cytokine-inducible negative regulation of cytokine signaling |
|  | Gene | Drug or compound | Gene | Drug or compound | Gene | Drug or compound |
| Known CD-drug target | IL17A | Secukinumab | S1PR5 <br> FCGR3A | Ozanimod <br> IgG class mAbs* | $C D 3 D / E / G$ <br> ITGAE <br> CCR9 <br> TGFBR1 | NI-0401 <br> Etrolizumab <br> Vercirnon <br> Mongersen*** |
| Candidate for drug repositioning | DNAJB1 <br> SIK1 <br> HSP90AA1 <br> PTGER4 <br> PDE4D | Apatorsen <br> Dabrafanib <br> Nedocromil <br> Rivenprost; Limaprost; <br> Dinoproston <br> Apremilast | $\begin{aligned} & \hline \text { CCL5 } \\ & \text { FGR } \\ & \text { FCGR3A } \\ & \text { ITGB2 } \\ & \\ & \text { ADRB2 } \end{aligned}$ | Heparin compounds <br> Dasatinib <br> IgG class mAbs** <br> Lifitegrast <br> Beta-2 adrenergic receptor blockers | CCL5 <br> ADRB1 <br> ALOX5AP <br> SLAMF7 <br> MDM4 | Heparin compounds <br> STD-101-D1 <br> Fiboflapon <br> Elotuzumab <br> ALRN-6924 |

Legend: Ileal mucosal Th17 cells, peripheral blood cytotoxic T lymphocytes (CTL) and ileal mucosal CTL show the highest number of significantly overexpressed CD-risk genes. The top 5 most significantly overexpressed CD-risk genes are shown in the first row of this table; Per cell type, the top 5 most significantly overexpressed known CD-drug targets and candidates for drug repositioning are shown. Selection of CD-risk genes is explained in 'Supplementary Methods: CD-risk genes'. 'Known CD-drug target' refers to genes encoding targets for drugs currently approved or under investigation for treatment of CD in humans. 'Candidate for drug repositioning' refers to genes encoding targets for drugs currently approved or under investigation in humans for other diseases than CD. (see 'Supplementary Methods: Drug-target genes')
CD: Crohn's disease; Th17: T-helper 17 cells; CTL: cytotoxic T lymphocyte
*[e.g. Adalimumab; Etanercept; Natalizumab]
**[e.g. Alefacept; Alemtuzumab]
***indirect target

Figure 1: Flow chart illustrating procedure of T-cell isolation and single-cell RNA sequencing


3 Crohn's disease patients


Peripheral blood

Intestinal mucosal biopsies


Step 1
Step 2
Step 3


## Supplementary Methods:

For details of antibodies, reagents, kits and software used see Supplementary Table 2.

## Patient selection and sample collection

For this study, we recruited one male and two female patients (ages 36, 25, and 48, respectively) with mild to moderate Crohn's disease (CD). Written informed consent was obtained and ethical approval was granted by the University Medical Center Groningen Ethics Committee. All three patients had been diagnosed with histologically proven ileal CD at least five years earlier. None had undergone surgical resections. For each patient, five pinch biopsies were collected from mildly inflamed terminal ileum: the most common site of inflammation in CD and a clear anatomical landmark.

Biopsies were collected into RPMI 1640 medium on ice and processed immediately. 10 mL of peripheral blood was collected subsequently in tubes containing 158 USP units lithiumheparin.

## Tissue processing

lleal biopsies were dissociated into single cells following a previously published protocol ${ }^{1}$, separating IEL and LPL fractions using EDTA+DTT and collagenase digestion. RNAse-mediated RNA degradation was limited by adding $15 \mu$ I RNAse Superase ${ }^{\text {TM }}$ before collagenase digestion. PBL were isolated using density gradient centrifugation with Lymphoprep ${ }^{\text {TM }}$ solution. Tissue processing, except for collagenase incubation, was performed on ice.

## Flow Cytometry of single-cell suspensions

All cell suspensions (IEL, LPL and PBL) were stained with the same antibody panel comprising propidium iodide and monoclonal antibodies to TCR $\alpha \beta, \mathrm{CD} 3, \mathrm{CD} 8 \alpha, \mathrm{CD} \beta \beta, \mathrm{CD} 19, \mathrm{CD} 45 \mathrm{RO}$, CD62L and CD326.

Cells were sorted using the MoFlo Astrios (Beckman Coulter, Inc.), using forward- and sidescatter signals to define lymphocyte fraction and exclude unwanted events such as debris, non-viable cells and doublets. CD3+TCR $\alpha \beta+$ lymphocytes were sorted one-cell-per-well into 384 -well plates containing cell lysis buffer, on ice (see 'Single-cell RNA library preparation and sequencing') (Figure 1, step 1). To minimize cell perturbation, sorting was performed at
low pressures. After sorting, each cell was collected in a well containing lysis buffer consisting of dNTP mix, Oligo dT primer, Triton X-100 and RNase inhibitor.

## Single-cell RNA library preparation and sequencing

Single-cell transcriptome libraries were created using a protocol based on Smart-Seq2 library preparation using $3^{\prime}$-paired-end sequencing ${ }^{2}$. After a 3 -minute incubation/ligation step at $72^{\circ} \mathrm{C}$, a TSO-primer containing Unique Molecular Identifiers (UMIs) was bound to the poly-A tail of RNA transcripts, after which these were reverse transcribed using SmartScribe reverse transcriptase. Next, the barcoded complementary DNA (cDNA) were amplified using BC-PCR primers. To eliminate short fragments, cDNA products were purified with 0.8 X ratio Agencourt Ampure XP beads. Following purification, tagmented libraries were constructed with the Nextera XT DNA preparation kit. To allow multiplexed high-throughput sequencing, cells were pooled with N7xx Nextera primer barcoding, enabling in silico sorting. Following amplification, products were cleaned with 0.6X ratio Agencourt Ampure XP beads. To check for size distribution of the cDNA product, the product was measured repeatedly on a PerkinElmer LabChip GX high-sensitivity DNA chip. After final quality check of amplified and purified products, pools were combined into superpools (8 barcoded pools/superpool-672 cells/superpool) and sequenced on the Illumina NextSeq500 sequencer with 400M 75bp paired-end reads.

## scRNAseq de-multiplexing pipeline

We obtained sequencing data for 5,292 single cells, with an average of $\sim 400,000$ reads per cell (Figure 1, step 2). Sequencing data was processed through a de-multiplexing pipeline. Reads with a Hamming distance >1 and an average quality score $\leq 10$ were excluded. Trimmed fastQ files were aligned to the human reference genome (Ensemble release 75, GRCh37) using STAR (v. 2.5.1b) ${ }^{3}$ with default settings. Approximately $75 \%$ of reads mapped uniquely. Before gene quantification, Picardtools (v. 2.2.2) ${ }^{4}$ was used to sort aligned reads and flag individual cells and UMIs. Gene level quantification was performed using Dropseq and filtering read count on unique UMIs, resulting in a gene/cell UMI count matrix.

## Quality control

UMI counts were processed using Seurat ${ }^{5}$. To correct for cell-to-cell gene detection differences, we log-normalized UMI counts per cell and excluded genes expressed in <3 cells. To control for low quality cells and doublets, we excluded cells expressing <200 genes per cell, cells expressing $>2500$ genes per cell and cells with $>5 \%$ mitochondrial genes. (Figure 1, step 2). We performed a principal component (PC) analysis and found that patient/batch, tissue-of-origin, and number of UMIs were the major drivers among the first 6 PCs. For our analyses, we regressed out the number of UMIs and percentage mitochondrial expression. Interpatient differences were assessed in differential expression analyses. Since differential expression between different tissues-of-origin may be partially driven by altered gene expression induced by collagenase digestion, we excluded 127 genes previously found to be influenced by collagenase digestion ${ }^{6}$.

## Integrating flow-cytometry and RNA expression data

Flow-cytometry data was analyzed using Kaluza software (Beckman Coulter Inc.). Positivity for any epitope was determined by visual inspection of plots with staining intensities. This adjudication process was cross-checked by a flow-cytometry expert. We used Summit software (Beckman Coulter Inc.) to extract intensity data per cell into a CSV file format. Data on positivity for epitope per cell was merged with metadata of the Seurat data file.

## Clustering

Cells were clustered using a K-nearest-neighbor-based method ${ }^{5}$ (Figure 1, step 3). Clustering was done with the PCs that were significant in a null-distribution determined through JackStraw analysis. We varied clustering resolution between 0.6 and 1.2 , and settled on 0.6 because higher resolution produced clusters defined by marginal differential gene expression. Different subsets (based on tissue-of-origin and the CD8 $\alpha \beta$ epitope) were clustered separately to check for subset-specific cell types and/or states. tSNE reduction was used for visualization purposes.

## Identification of T-cell subtypes in intestinal mucosa

In order to stratify cell types, we first defined cells with a quiescent profile based on expression of CCR7 and cells with an effector profile based on expression of CD160. The mucosal T cells could be divided into four T-cell subtypes: T-helper 17 (Th17) cells, Treg cells
on a quiescent background (Treg/Quiescent), Cytotoxic $T$ cells (CTL), and a group of REG1A/1B-expressing cells. (Figure 1, Supplementary Figure 1, Supplementary Table 1).

CTL were identified based on expression of EOMES, PRF1 and TBX21; cytotoxic enzymes such as GNLY, GZMH and GZMB; and genes for cytokines with a strong chemoattractant function such as CCL4 and CCL5 or XCL1, XCL2 and ITGA1. Treg/Quiescent cells were characterized by expression of TNFRSF4, FOXP3, CCR7, IL6ST, NOG and SELL. Th17 cells were characterized by expression of IL17A, IL22 and IRF4 and transcription factors typical for Th17 cell function such as NR4A2 and CREM.

Finally, we identified a much smaller group of cells that could not be defined based on published genetic markers. These cells express high levels of REG1A/1B and show coexpression of $C D 3 E / G$ and $E P C A M$. Immunofluorescence staining of ileal mucosa of CD patients confirmed the presence of these cells in the mucosa, expressing both CD3 and REG1A proteins.

## Identification of T-cell subtypes in peripheral blood

Within the PBL population, we found CTL, Quiescent cells, Effector/Treg cells and Treg/Quiescent cells (Figure 1, Supplementary Table 1). Quiescent T cells were characterized based on expression of CCR7, IL6ST, SELL, NOG and TCF7 (Supplementary Table 1). A second cluster of cells with a quiescent profile express TNFRSF4, and these were characterized as Treg/Quiescent cells through expression of TNFRSF4 and LTB, MTA2 and HNRPH1. Effector/Treg were characterized by expression of TNFRSF4 and ITGAE, IL32, FOXP3, PRDM1 and CMTM6. Finally, CTL were characterized based on high expression of marker genes such as EOMES, PRF1 and TBX21 and the above-mentioned genes GNLY, GZMH, GZMB, CCL4 and CCL5 (Supplementary Table 1).

## Differential expression analysis

Differential expression analysis was done using the MAST function in Seurat (Figure 1, step 3). Differential expression was calculated between tissues-of-origin and cell types. To classify only genes that are expressed at least moderately, we filtered out genes expressed in less than 1\% of the cells. After Bonferroni correction for multiple testing, results were considered significant at an adjusted $P$-value $<0.05$. Regressing out the effects of individual patient and sex did not induce major differences in gene expression signatures: 94\% of the T-cell-
subtype-specific gene-expression signatures overlapped between analyses (data not shown). To capture subtle changes in expression, we used the non-regressed data for subsequent analyses.

## CD-risk genes

Through literature search, we identified 179 CD-risk genes. From each genome-wide association study (GWAS) risk locus, we selected the gene implicated through coding variants or functional variants. If multiple genes were implicated within a locus, the genes implicated through functional evidence were selected. Three loci remained in which two genes were implicated, and all were included in further analysis. If no functional or coding data was available, the most likely implicated gene (generally implicated indirectly through functional studies) was selected. Since scRNAseq detects overexpression more robustly than underexpression, and a previous study showed that CD-risk genes dysregulated between CD intestinal mucosa and healthy intestinal mucosa are generally upregulated, we focus on upregulated genes ${ }^{7}$.

## Drug-target genes

We aligned IBD drug-target genes extracted from OpenTargets ${ }^{8}$ ( $n=2,712$ ) and Drugbank ${ }^{9}$, to differentially expressed genes, and subsequently selected genes encoding proteins targeted by drugs currently available for (clinical trials in) humans.

## Comparison with scRNAseq dataset of T cells from healthy subjects

We studied publicly available scRNAseq data of epitopic CD4-positive naïve T cells for their mRNA expression of genes typically associated with epitopic CD8 $\alpha \beta$-positive T cells ${ }^{10}$.

## Enrichment for CD-risk gene expression

We assessed whether T-cell subtypes showed enrichment for expression of CD-risk genes. We created null-distributions by randomly selecting sets the size of the differentially expressed genes per cell type from the total set of 12,531 genes. Empirical $P$-values of overrepresentation of CD-risk genes within cell-type-specific differentially expressed gene sets were derived from the null-distributions generated from $10^{5}$ rounds of random sampling.

Data and software availability

## ACCEPTED MANUSCRIPT

The scripts used can be found at https://github.com/WeersmaLabIBD/SingleCell. Summit can be obtained from Beckman Coulter. The raw data is available at https://ega-archive.org (EGAS00001002702).

## References used in Supplementary Methods

1. Raine T, et al. Gut 2015;64:250-259
2. Picelli S, et al. Nat Methods 2013;10:1096-8
3. Dobin A, et al. Bioinformatics 2013;29:15-21
4. Picard Tools - By Broad Institute. Available at: http://broadinstitute.github.io/picard/ [Accessed March 9, 2018].
5. Satija R, Farrell JA, et al. Nat Biotechnol 2015;33:495-502
6. Brink SC van den, et al. Nat Methods 2017;14:935-936
7. Holgersen K, et al. J Crohns Colitis 2015;9:492-506.
8. Koscielny G, et al. Nucleic Acids Res 2017;45:D985-D994
9. Wishart DS, et al. Nucleic Acids Res 2018;46:D1074-D1082.
10. Zheng GXY, et al. Nat Commun 2017;8:14049.

Legend: T-cell subsets were characterized based on marker genes (see Supplementary Methods). Genes shown are significantly overexpressed in the specified cell type relative to all other cell types. The 'Gene annotation' column indicates whether a gene is a CD-risk gene, a drug-target gene (as described Supplementary Methods sections: 'CD-risk genes' and 'Drug-target genes'), a transcription factor or encodes a cytokine.
$\mathbf{X}$ : risk gene; $\triangleleft:$ drug target; $\odot:$ transcription factor; *:cytokine

| Gene | Average log fold change | Adjusted p-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| GNLY | $3.11 \mathrm{E}+00$ | 3.60E-201 | Peripheral blood | CTL |  |
| GZMH | $2.43 \mathrm{E}+00$ | 3.23E-166 | Peripheral blood | CTL |  |
| NKG7 | $1.89 \mathrm{E}+00$ | $2.24 \mathrm{E}-136$ | Peripheral blood | CTL |  |
| PRF1 | $1.88 \mathrm{E}+00$ | $2.44 \mathrm{E}-123$ | Peripheral blood | CTL |  |
| GZMB | $2.26 \mathrm{E}+00$ | 2.41E-106 | Peripheral blood | CTL |  |
| ADGRG1 | $1.89 \mathrm{E}+00$ | 1.56E-101 | Peripheral blood | CTL |  |
| S1PR5 | $1.94 \mathrm{E}+00$ | 4.14E-82 | Peripheral blood | CTL | $\triangleleft$ |
| CX3CR1 | $1.64 \mathrm{E}+00$ | 1.31E-67 | Peripheral blood | CTL |  |
| CCL5 | 9.36E-01 | $1.64 \mathrm{E}-66$ | Peripheral blood | CTL | * |
| TBX21 | $1.28 \mathrm{E}+00$ | 3.71E-64 | Peripheral blood | CTL | - |
| FGR | $1.55 \mathrm{E}+00$ | $1.96 \mathrm{E}-58$ | Peripheral blood | CTL |  |
| FGFBP2 | $1.77 \mathrm{E}+00$ | 1.38E-57 | Peripheral blood | CTL |  |
| EFHD2 | $1.36 \mathrm{E}+00$ | 2.61E-56 | Peripheral blood | CTL |  |
| TRGC2 | $1.57 \mathrm{E}+00$ | 1.10E-54 | Peripheral blood | CTL |  |
| FCRL6 | $1.33 \mathrm{E}+00$ | 1.87E-51 | Peripheral blood | CTL |  |
| FCGR3A | $1.52 \mathrm{E}+00$ | 5.86E-49 | Peripheral blood | CTL | $\triangleleft$ |
| PLEK | $1.40 \mathrm{E}+00$ | $1.11 \mathrm{E}-45$ | Peripheral blood | CTL | - |
| CST7 | $1.05 \mathrm{E}+00$ | $1.28 \mathrm{E}-43$ | Peripheral blood | CTL |  |
| ITGB2 | $9.32 \mathrm{E}-01$ | 1.20E-42 | Peripheral blood | CTL |  |
| GZMA | $1.48 \mathrm{E}+00$ | $2.84 \mathrm{E}-42$ | Peripheral blood | CTL |  |
| FLVCR2 | 5.21E-01 | 4.90E-38 | Peripheral blood | CTL |  |
| PRSS23 | $1.20 \mathrm{E}+00$ | $1.63 \mathrm{E}-35$ | Peripheral blood | CTL |  |
| CTSW | $1.06 \mathrm{E}+00$ | 3.00E-35 | Peripheral blood | CTL | $x$ |
| CCL4 | $1.26 \mathrm{E}+00$ | $1.35 \mathrm{E}-34$ | Peripheral blood | CTL | * |
| ADRB2 | $1.23 \mathrm{E}+00$ | 7.44E-33 | Peripheral blood | CTL |  |
| PFN1P1 | $2.53 \mathrm{E}-01$ | 4.83E-32 | Peripheral blood | CTL |  |
| SPON2 | $1.38 \mathrm{E}+00$ | 9.60E-31 | Peripheral blood | CTL |  |
| KLRD1 | $1.15 \mathrm{E}+00$ | 2.67E-29 | Peripheral blood | CTL |  |
| TRGC1 | 7.60E-01 | 3.39E-29 | Peripheral blood | CTL |  |
| FLNA | 8.16E-01 | 1.63E-28 | Peripheral blood | CTL |  |
| ARL4C | 9.80E-01 | 2.40E-28 | Peripheral blood | CTL |  |
| SYT8 | 5.63E-01 | 1.40E-24 | Peripheral blood | CTL |  |
| SYNE2 | 7.85E-01 | 8.38E-23 | Peripheral blood | CTL |  |
| ZEB2 | $9.52 \mathrm{E}-01$ | 3.86E-22 | Peripheral blood | CTL | $\bullet$ |


| Gene | Average <br> log fold <br> change | Adjusted <br> p-value |  | Compartment | Cell type |
| :--- | :--- | :--- | :--- | :--- | :---: | | Gene |
| :---: |
| annotation |
|  |
| ASCL2 | |  |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- |
| LITAF | $8.95 \mathrm{E}-01$ | $5.10 \mathrm{E}-22$ | Peripheral blood | CTL |

$\left.\begin{array}{|llllll|}\hline \text { Gene } & \begin{array}{l}\text { Average } \\ \text { log fold } \\ \text { change }\end{array} & \begin{array}{l}\text { Adjusted } \\ \text { p-value }\end{array} & & \text { Compartment } & \text { Cell type }\end{array} \begin{array}{c}\text { Gene } \\ \text { annotation } \\ \\ \text { RP11.81H14.2 }\end{array} \begin{array}{lllll} & & & & \\ \text { NCR1 } & 3.22 \mathrm{E}-01 & 1.08 \mathrm{E}-10 & \text { Peripheral blood } & \text { CTL }\end{array}\right]$

| Gene | Average <br> log fold <br> change | Adjusted <br> p-value |  | Compartment | Cell type |
| :--- | :--- | :--- | :--- | :--- | :--- | | Gene |
| :---: |
| annotation |
|  |
| LILRB1 | |  |  |  |  |  |
| :--- | :--- | :--- | :--- | :--- |
| S1PR1 | $6.59 \mathrm{E}-01$ | $7.93 \mathrm{E}-07$ | Peripheral blood | CTL |

$\left.\begin{array}{|llllll|}\hline \text { Gene } & \begin{array}{l}\text { Average } \\ \text { log fold } \\ \text { change }\end{array} & \begin{array}{l}\text { Adjusted } \\ \text { p-value }\end{array} & & \text { Compartment } & \text { Cell type }\end{array} \quad \begin{array}{c}\text { Gene } \\ \text { annotation } \\ \\ \text { SELPLG }\end{array} \begin{array}{lllll} & & & & \\ \text { DGKZ } & 3.53 \mathrm{E}-01 & 1.11 \mathrm{E}-04 & \text { Peripheral blood } & \text { CTL }\end{array}\right]$

| Gene | Average log fold change | Adjusted p-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| GSE1 | $3.72 \mathrm{E}-01$ | 5.59E-03 | Peripheral blood | CTL |  |
| ARPC5L | $4.34 \mathrm{E}-01$ | 6.59E-03 | Peripheral blood | CTL |  |
| MIR4435.2HG | 3.80E-01 | 6.86E-03 | Peripheral blood | CTL |  |
| LYPLA2 | 3.00E-01 | 7.59E-03 | Peripheral blood | CTL |  |
| MTATP6P1 | 3.80E-01 | 9.73E-03 | Peripheral blood | CTL |  |
| ARHGAP30 | $3.22 \mathrm{E}-01$ | $1.04 \mathrm{E}-02$ | Peripheral blood | CTL |  |
| PGAM1 | $3.34 \mathrm{E}-01$ | $1.15 \mathrm{E}-02$ | Peripheral blood | CTL |  |
| SLC25A20 | $4.36 \mathrm{E}-01$ | 1.16E-02 | Peripheral blood | CTL |  |
| CYTH1 | 3.06E-01 | 1.17E-02 | Peripheral blood | CTL |  |
| RNF213 | $2.69 \mathrm{E}-01$ | 1.17E-02 | Peripheral blood | CTL |  |
| SYTL1 | 5.87E-01 | 1.32E-02 | Peripheral blood | CTL |  |
| GAB3 | 5.56E-01 | 1.38E-02 | Peripheral blood | CTL |  |
| АСТВ | $2.86 \mathrm{E}-01$ | $1.47 \mathrm{E}-02$ | Peripheral blood | CTL |  |
| TPM3 | $4.14 \mathrm{E}-01$ | $1.54 \mathrm{E}-02$ | Peripheral blood | CTL |  |
| ATM | 3.20E-01 | $1.58 \mathrm{E}-02$ | Peripheral blood | CTL |  |
| BROX | 2.70E-01 | $1.66 \mathrm{E}-02$ | Peripheral blood | CTL |  |
| TTC16 | 5.03E-01 | 1.73E-02 | Peripheral blood | CTL |  |
| STX10 | $4.71 \mathrm{E}-01$ | $1.88 \mathrm{E}-02$ | Peripheral blood | CTL |  |
| PIK3R5 | 4.01E-01 | 1.94E-02 | Peripheral blood | CTL |  |
| ARHGEF1 | $3.85 \mathrm{E}-01$ | 1.96E-02 | Peripheral blood | CTL |  |
| CAPN2 | $4.79 \mathrm{E}-01$ | 1.97E-02 | Peripheral blood | CTL |  |
| MTND4P12 | 2.70E-01 | 2.08E-02 | Peripheral blood | CTL |  |
| PRKCH | $3.21 \mathrm{E}-01$ | 2.47E-02 | Peripheral blood | CTL | $\triangleleft$ |
| FAM65B | $3.11 \mathrm{E}-01$ | $2.63 \mathrm{E}-02$ | Peripheral blood | CTL |  |
| STARD7 | 4.03E-01 | $2.75 \mathrm{E}-02$ | Peripheral blood | CTL |  |
| IL2RB | $4.62 \mathrm{E}-01$ | $2.78 \mathrm{E}-02$ | Peripheral blood | CTL | $\triangleleft$ |
| MOB3A | $3.54 \mathrm{E}-01$ | 2.93E-02 | Peripheral blood | CTL |  |
| ACTN4 | $5.91 \mathrm{E}-01$ | 3.02E-02 | Peripheral blood | CTL |  |
| SLC2A1 | $4.24 \mathrm{E}-01$ | 3.22E-02 | Peripheral blood | CTL |  |
| F2R | $3.31 \mathrm{E}-01$ | 3.40E-02 | Peripheral blood | CTL |  |
| FAM49B | 4.98E-01 | $3.78 \mathrm{E}-02$ | Peripheral blood | CTL |  |
| ANKRD20A11P | 2.99E-01 | $4.46 \mathrm{E}-02$ | Peripheral blood | CTL |  |
| RGS9 | $3.54 \mathrm{E}-01$ | 4.52E-02 | Peripheral blood | CTL | - |
| RPS27L | 3.91E-01 | 4.65E-02 | Peripheral blood | CTL |  |
| C11orf21 | 4.50E-01 | $4.68 \mathrm{E}-02$ | Peripheral blood | CTL |  |
| TAF10 | 4.29E-01 | 4.70E-02 | Peripheral blood | CTL |  |
| CCL5 | $1.14 \mathrm{E}+00$ | 1.70E-120 | Intestinal mucosa | CTL | * |
| CD160 | $1.51 \mathrm{E}+00$ | 3.82E-70 | Intestinal mucosa | CTL |  |
| TMSB4XP8 | 4.07E-01 | 3.00E-51 | Intestinal mucosa | CTL |  |
| ADRB1 | $1.06 \mathrm{E}+00$ | $1.67 \mathrm{E}-43$ | Intestinal mucosa | CTL |  |

\(\left.$$
\begin{array}{|lllllc|}\hline \text { Gene } & \begin{array}{l}\text { Average } \\
\text { log fold } \\
\text { change }\end{array}
$$ \& \begin{array}{l}Adjusted <br>

p-value\end{array} \& \& Compartment \& Cell type\end{array}\right]\)| Gene |
| :---: |
| annotation |$|$


| Gene | Average log fold change | Adjusted $p$-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| RP11.94L15.2 | 6.82E-01 | 2.13E-11 | Intestinal mucosa | CTL |  |
| SAR1A | $2.89 \mathrm{E}-01$ | 4.62E-11 | Intestinal mucosa | CTL |  |
| DENND2D | 4.37E-01 | 6.73E-11 | Intestinal mucosa | CTL |  |
| COTL1 | $5.56 \mathrm{E}-01$ | $1.49 \mathrm{E}-10$ | Intestinal mucosa | CTL |  |
| MDM4 | 4.08E-01 | 6.94E-10 | Intestinal mucosa | CTL |  |
| JAML | 5.38E-01 | 7.68E-10 | Intestinal mucosa | CTL |  |
| SLC7A8 | $3.36 \mathrm{E}-01$ | 9.89E-10 | Intestinal mucosa | CTL |  |
| CYBA | $3.42 \mathrm{E}-01$ | 1.25E-09 | Intestinal mucosa | CTL |  |
| AUTS2 | $4.64 \mathrm{E}-01$ | 2.15E-09 | Intestinal mucosa | CTL |  |
| CALR | $2.61 \mathrm{E}-01$ | 7.04E-09 | Intestinal mucosa | CTL |  |
| AFAP1L2 | $3.57 \mathrm{E}-01$ | 9.01E-09 | Intestinal mucosa | CTL |  |
| TBL1XR1 | $3.72 \mathrm{E}-01$ | 1.20E-08 | Intestinal mucosa | CTL |  |
| CD3E | $3.21 \mathrm{E}-01$ | $1.93 \mathrm{E}-08$ | Intestinal mucosa | CTL | $\triangleleft$ |
| RHOC | 6.53E-01 | $1.99 \mathrm{E}-08$ | Intestinal mucosa | CTL |  |
| CD244 | $4.98 \mathrm{E}-01$ | 2.06E-08 | Intestinal mucosa | CTL |  |
| DAPK2 | 5.92E-01 | 2.83E-08 | Intestinal mucosa | CTL |  |
| TRAC | $3.19 \mathrm{E}-01$ | 2.98E-08 | Intestinal mucosa | CTL |  |
| CD96 | 3.60E-01 | $4.43 \mathrm{E}-08$ | Intestinal mucosa | CTL |  |
| KLRB1 | $3.78 \mathrm{E}-01$ | 5.35E-08 | Intestinal mucosa | CTL |  |
| MIDN | $4.30 \mathrm{E}-01$ | 2.67E-07 | Intestinal mucosa | CTL |  |
| YWHAH | 6.03E-01 | 5.21E-07 | Intestinal mucosa | CTL |  |
| AC092580.4 | 5.70E-01 | $5.41 \mathrm{E}-07$ | Intestinal mucosa | CTL |  |
| SEPT1 | $3.04 \mathrm{E}-01$ | $1.41 \mathrm{E}-06$ | Intestinal mucosa | CTL |  |
| PPP3CA | $3.09 \mathrm{E}-01$ | $1.48 \mathrm{E}-06$ | Intestinal mucosa | CTL |  |
| FASLG | $6.39 \mathrm{E}-01$ | 8.39E-06 | Intestinal mucosa | CTL | * |
| CD248 | $3.08 \mathrm{E}-01$ | 9.99E-06 | Intestinal mucosa | CTL |  |
| TMEM120B | $3.22 \mathrm{E}-01$ | $1.37 \mathrm{E}-05$ | Intestinal mucosa | CTL |  |
| GAB3 | $3.92 \mathrm{E}-01$ | $1.62 \mathrm{E}-05$ | Intestinal mucosa | CTL |  |
| TGFBR1 | 5.06E-01 | $2.58 \mathrm{E}-05$ | Intestinal mucosa | CTL |  |
| CTD.2369P2.2 | $2.68 \mathrm{E}-01$ | 3.63E-05 | Intestinal mucosa | CTL |  |
| SBNO1 | 3.46E-01 | 3.81E-05 | Intestinal mucosa | CTL |  |
| FMNL3 | $2.68 \mathrm{E}-01$ | $4.74 \mathrm{E}-05$ | Intestinal mucosa | CTL |  |
| ER01A | $3.54 \mathrm{E}-01$ | 4.88E-05 | Intestinal mucosa | CTL |  |
| PSME2 | 3.69E-01 | 5.49E-05 | Intestinal mucosa | CTL |  |
| CD101 | $4.68 \mathrm{E}-01$ | 6.47E-05 | Intestinal mucosa | CTL |  |
| TRGC1 | $2.72 \mathrm{E}-01$ | 7.17E-05 | Intestinal mucosa | CTL |  |
| TTI2 | $3.61 \mathrm{E}-01$ | 9.01E-05 | Intestinal mucosa | CTL |  |
| RP11.841020.2 | 3.57E-01 | 1.03E-04 | Intestinal mucosa | CTL |  |
| FKBP1A | 4.29E-01 | 1.07E-04 | Intestinal mucosa | CTL | $\triangleleft$ |
| NABP1 | $3.31 \mathrm{E}-01$ | 1.13E-04 | Intestinal mucosa | CTL |  |


| Gene | Average log fold change | Adjusted p-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| BUB3 | $2.53 \mathrm{E}-01$ | 1.28E-04 | Intestinal mucosa | CTL |  |
| FYN | $3.77 \mathrm{E}-01$ | 1.60E-04 | Intestinal mucosa | CTL |  |
| LAG3 | $3.12 \mathrm{E}-01$ | 1.65E-04 | Intestinal mucosa | CTL |  |
| RHOF | 2.87E-01 | 2.25E-04 | Intestinal mucosa | CTL |  |
| CEPT1 | $2.56 \mathrm{E}-01$ | 2.38E-04 | Intestinal mucosa | CTL |  |
| TMEM33 | $3.38 \mathrm{E}-01$ | 2.57E-04 | Intestinal mucosa | CTL |  |
| FNBP1 | $3.28 \mathrm{E}-01$ | 2.93E-04 | Intestinal mucosa | CTL |  |
| IL18RAP | $3.44 \mathrm{E}-01$ | 3.06E-04 | Intestinal mucosa | CTL |  |
| GUK1 | $3.39 \mathrm{E}-01$ | 3.24E-04 | Intestinal mucosa | CTL |  |
| AP1G1 | $2.89 \mathrm{E}-01$ | 4.20E-04 | Intestinal mucosa | CTL |  |
| TRGC2 | 5.15E-01 | 4.26E-04 | Intestinal mucosa | CTL |  |
| ST3GAL5 | $3.32 \mathrm{E}-01$ | 4.88E-04 | Intestinal mucosa | CTL |  |
| KLRC1 | $3.54 \mathrm{E}-01$ | 5.28E-04 | Intestinal mucosa | CTL |  |
| DNAJC3 | $3.57 \mathrm{E}-01$ | 6.14E-04 | Intestinal mucosa | CTL |  |
| SLC35F6 | $3.29 \mathrm{E}-01$ | 6.31E-04 | Intestinal mucosa | CTL |  |
| GPR82 | $3.60 \mathrm{E}-01$ | 6.73E-04 | Intestinal mucosa | CTL |  |
| DTX3L | $4.27 \mathrm{E}-01$ | 7.17E-04 | Intestinal mucosa | CTL |  |
| CD63 | $5.61 \mathrm{E}-01$ | 9.29E-04 | Intestinal mucosa | CTL |  |
| AP4B1 | $3.02 \mathrm{E}-01$ | 9.53E-04 | Intestinal mucosa | CTL |  |
| PTPN6 | 2.93E-01 | 1.20E-03 | Intestinal mucosa | CTL |  |
| TROVE2 | $2.87 \mathrm{E}-01$ | $1.49 \mathrm{E}-03$ | Intestinal mucosa | CTL |  |
| EIF1AD | $3.55 \mathrm{E}-01$ | $1.54 \mathrm{E}-03$ | Intestinal mucosa | CTL |  |
| C9orf78 | $4.05 \mathrm{E}-01$ | $2.44 \mathrm{E}-03$ | Intestinal mucosa | CTL |  |
| PARP9 | $3.83 \mathrm{E}-01$ | $3.13 \mathrm{E}-03$ | Intestinal mucosa | CTL |  |
| PLCG2 | $3.43 \mathrm{E}-01$ | $4.57 \mathrm{E}-03$ | Intestinal mucosa | CTL | $x$ |
| TMED2 | $3.23 \mathrm{E}-01$ | 4.82E-03 | Intestinal mucosa | CTL |  |
| SPN | $3.05 \mathrm{E}-01$ | 5.05E-03 | Intestinal mucosa | CTL |  |
| FYCO1 | $2.60 \mathrm{E}-01$ | 5.27E-03 | Intestinal mucosa | CTL |  |
| XYLT2 | $2.86 \mathrm{E}-01$ | 5.65E-03 | Intestinal mucosa | CTL |  |
| AC020571.3 | 5.17E-01 | 5.86E-03 | Intestinal mucosa | CTL |  |
| DHRS7 | $4.46 \mathrm{E}-01$ | 7.16E-03 | Intestinal mucosa | CTL |  |
| WDR41 | $4.20 \mathrm{E}-01$ | 7.48E-03 | Intestinal mucosa | CTL |  |
| CD9 | $5.51 \mathrm{E}-01$ | 8.02E-03 | Intestinal mucosa | CTL |  |
| TAPBP | $2.81 \mathrm{E}-01$ | 9.49E-03 | Intestinal mucosa | CTL |  |
| SOCS1 | $3.59 \mathrm{E}-01$ | 9.51E-03 | Intestinal mucosa | CTL | $x$ |
| ZSWIM1 | $3.15 \mathrm{E}-01$ | $1.02 \mathrm{E}-02$ | Intestinal mucosa | CTL |  |
| TNFSF14 | $4.70 \mathrm{E}-01$ | $1.16 \mathrm{E}-02$ | Intestinal mucosa | CTL | * |
| PSMA3 | $2.89 \mathrm{E}-01$ | 1.21E-02 | Intestinal mucosa | CTL |  |
| ANAPC11 | $4.20 \mathrm{E}-01$ | 1.70E-02 | Intestinal mucosa | CTL |  |
| GPR34 | $5.20 \mathrm{E}-01$ | 1.73E-02 | Intestinal mucosa | CTL |  |


| Gene | Average log fold change | Adjusted $p$-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| GYG1 | 5.52E-01 | 1.86E-02 | Intestinal mucosa | CTL |  |
| GNGT2 | $4.30 \mathrm{E}-01$ | 2.03E-02 | Intestinal mucosa | CTL |  |
| PDIA3 | $2.79 \mathrm{E}-01$ | 2.91E-02 | Intestinal mucosa | CTL |  |
| MAN1A1 | $2.90 \mathrm{E}-01$ | 3.13E-02 | Intestinal mucosa | CTL |  |
| GSTP1 | $4.04 \mathrm{E}-01$ | 3.50E-02 | Intestinal mucosa | CTL |  |
| NOP10 | $2.90 \mathrm{E}-01$ | 3.75E-02 | Intestinal mucosa | CTL |  |
| MARCH2 | $3.11 \mathrm{E}-01$ | 4.57E-02 | Intestinal mucosa | CTL |  |
| DOCK5 | 3.62E-01 | 4.63E-02 | Intestinal mucosa | CTL |  |
| SELL | $1.17 \mathrm{E}+00$ | 3.05E-97 | Peripheral blood | Quiescent |  |
| CCR7 | $1.02 \mathrm{E}+00$ | 5.98E-85 | Peripheral blood | Quiescent |  |
| NOG | $1.22 \mathrm{E}+00$ | 5.86E-72 | Peripheral blood | Quiescent |  |
| RP11.360D2.2 | $4.65 \mathrm{E}-01$ | 7.01E-64 | Peripheral blood | Quiescent |  |
| RP11.234A1.1 | 3.96E-01 | 6.32E-59 | Peripheral blood | Quiescent |  |
| RP4.765C7.2 | 3.47E-01 | 2.27E-57 | Peripheral blood | Quiescent |  |
| RPS27 | 3.81E-01 | 9.92E-57 | Peripheral blood | Quiescent |  |
| RPS14P3 | 3.66E-01 | 1.43E-55 | Peripheral blood | Quiescent |  |
| RP11.543P15.1 | 2.89E-01 | 4.01E-53 | Peripheral blood | Quiescent |  |
| FAM65B | 5.63E-01 | $1.78 \mathrm{E}-40$ | Peripheral blood | Quiescent |  |
| C16orf54 | 4.27E-01 | 1.47E-38 | Peripheral blood | Quiescent |  |
| RPL34 | 3.88E-01 | 5.75E-37 | Peripheral blood | Quiescent |  |
| RPS14 | $3.10 \mathrm{E}-01$ | 4.93E-36 | Peripheral blood | Quiescent |  |
| PCED1B.AS1 | 6.89E-01 | 1.32E-34 | Peripheral blood | Quiescent |  |
| RPL18A | 3.17E-01 | 2.83E-34 | Peripheral blood | Quiescent |  |
| RPL3P4 | $3.10 \mathrm{E}-01$ | 5.68E-34 | Peripheral blood | Quiescent |  |
| RPS25 | $3.60 \mathrm{E}-01$ | 6.06E-34 | Peripheral blood | Quiescent |  |
| CDC42SE1 | $2.91 \mathrm{E}-01$ | 2.47E-32 | Peripheral blood | Quiescent |  |
| RPS18 | $3.27 \mathrm{E}-01$ | 3.76E-31 | Peripheral blood | Quiescent |  |
| RPL31 | 4.80E-01 | 1.59E-30 | Peripheral blood | Quiescent |  |
| RPS28 | $4.60 \mathrm{E}-01$ | 1.21E-29 | Peripheral blood | Quiescent |  |
| RPL3 | 2.83E-01 | 1.49E-29 | Peripheral blood | Quiescent |  |
| C1orf56 | $2.92 \mathrm{E}-01$ | 4.64E-28 | Peripheral blood | Quiescent |  |
| MYC | 6.89E-01 | 2.67E-27 | Peripheral blood | Quiescent | - |
| RPL23A | 3.46E-01 | 3.09E-27 | Peripheral blood | Quiescent |  |
| NOSIP | 6.46E-01 | 4.69E-27 | Peripheral blood | Quiescent |  |
| RP4.594110.3 | 4.94E-01 | 6.23E-27 | Peripheral blood | Quiescent |  |
| TMSB10 | $3.17 \mathrm{E}-01$ | 1.23E-26 | Peripheral blood | Quiescent |  |
| RCAN3 | 5.23E-01 | 1.94E-26 | Peripheral blood | Quiescent |  |
| RPS6 | $3.42 \mathrm{E}-01$ | 7.94E-26 | Peripheral blood | Quiescent |  |
| RPL13A | $3.40 \mathrm{E}-01$ | 1.32E-24 | Peripheral blood | Quiescent |  |
| LEF1 | 6.36E-01 | 2.79E-24 | Peripheral blood | Quiescent | - |


| Gene | Average log fold change | Adjusted $p$-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| RPS15 | 4.14E-01 | $1.02 \mathrm{E}-23$ | Peripheral blood | Quiescent |  |
| RPL32 | $4.24 \mathrm{E}-01$ | $2.28 \mathrm{E}-23$ | Peripheral blood | Quiescent |  |
| RPS11 | $2.84 \mathrm{E}-01$ | 2.76E-23 | Peripheral blood | Quiescent |  |
| RPL37A | 4.97E-01 | 2.98E-23 | Peripheral blood | Quiescent |  |
| RPL23 | 3.40E-01 | 7.86E-23 | Peripheral blood | Quiescent |  |
| RPS29 | 4.15E-01 | 1.81E-22 | Peripheral blood | Quiescent |  |
| RPL10P3 | 4.05E-01 | 6.72E-22 | Peripheral blood | Quiescent |  |
| LDHB | 5.55E-01 | 2.62E-20 | Peripheral blood | Quiescent |  |
| IL6ST | 4.22E-01 | 3.06E-20 | Peripheral blood | Quiescent | * |
| AES | 3.82E-01 | 6.01E-20 | Peripheral blood | Quiescent |  |
| RPL13 | 3.01E-01 | 9.98E-20 | Peripheral blood | Quiescent |  |
| RPL30 | 4.69E-01 | 4.54E-19 | Peripheral blood | Quiescent |  |
| GIMAP7 | 3.68E-01 | 1.88E-18 | Peripheral blood | Quiescent |  |
| TRABD2A | 5.92E-01 | $4.56 \mathrm{E}-18$ | Peripheral blood | Quiescent |  |
| RPS3 | $3.16 \mathrm{E}-01$ | 5.59E-18 | Peripheral blood | Quiescent |  |
| RPS28P7 | $3.84 \mathrm{E}-01$ | 7.57E-18 | Peripheral blood | Quiescent |  |
| RPS13 | 4.57E-01 | 9.73E-18 | Peripheral blood | Quiescent |  |
| RPS21 | 4.48E-01 | $9.78 \mathrm{E}-18$ | Peripheral blood | Quiescent |  |
| LINC00861 | 5.82E-01 | 5.17E-17 | Peripheral blood | Quiescent |  |
| MDS2 | 5.25E-01 | 1.18E-16 | Peripheral blood | Quiescent |  |
| RPL5 | 4.58E-01 | 1.90E-16 | Peripheral blood | Quiescent |  |
| RASSF3 | 3.72E-01 | $3.96 \mathrm{E}-15$ | Peripheral blood | Quiescent |  |
| EIF2S3 | 3.18E-01 | 2.67E-14 | Peripheral blood | Quiescent |  |
| LIMD2 | $3.14 \mathrm{E}-01$ | $4.62 \mathrm{E}-14$ | Peripheral blood | Quiescent |  |
| RPL27A | 3.37E-01 | 5.34E-14 | Peripheral blood | Quiescent |  |
| RPL19 | 3.82E-01 | $7.94 \mathrm{E}-14$ | Peripheral blood | Quiescent |  |
| RPL15 | $2.99 \mathrm{E}-01$ | $1.27 \mathrm{E}-13$ | Peripheral blood | Quiescent |  |
| RPS16 | 3.56E-01 | $1.41 \mathrm{E}-13$ | Peripheral blood | Quiescent |  |
| TOB1 | 4.13E-01 | $1.48 \mathrm{E}-13$ | Peripheral blood | Quiescent |  |
| RPS12 | 3.85E-01 | $1.70 \mathrm{E}-13$ | Peripheral blood | Quiescent |  |
| RPL14 | $3.64 \mathrm{E}-01$ | $2.80 \mathrm{E}-13$ | Peripheral blood | Quiescent |  |
| RPL39 | 3.63E-01 | 3.23E-13 | Peripheral blood | Quiescent |  |
| RPL28 | 3.93E-01 | 3.28E-13 | Peripheral blood | Quiescent |  |
| RPL11 | 4.53E-01 | $3.56 \mathrm{E}-13$ | Peripheral blood | Quiescent |  |
| RPL27 | 3.39E-01 | 4.00E-13 | Peripheral blood | Quiescent |  |
| TCF7 | 3.73E-01 | 4.05E-13 | Peripheral blood | Quiescent | - |
| RP11.415F23.2 | 4.99E-01 | 5.53E-13 | Peripheral blood | Quiescent |  |
| AC005944.2 | 4.02E-01 | 1.64E-12 | Peripheral blood | Quiescent |  |
| RPL9 | $2.85 \mathrm{E}-01$ | 1.80E-12 | Peripheral blood | Quiescent |  |
| NELL2 | 5.30E-01 | $2.10 \mathrm{E}-12$ | Peripheral blood | Quiescent |  |


| Gene | Average log fold change | Adjusted p-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| CD27 | 3.79E-01 | 9.01E-12 | Peripheral blood | Quiescent |  |
| RPS20 | 3.03E-01 | $1.13 \mathrm{E}-11$ | Peripheral blood | Quiescent |  |
| CTD.2031P19.5 | $2.70 \mathrm{E}-01$ | $1.39 \mathrm{E}-11$ | Peripheral blood | Quiescent |  |
| RPL38 | $4.09 \mathrm{E}-01$ | 1.39E-11 | Peripheral blood | Quiescent |  |
| RPL10A | $3.15 \mathrm{E}-01$ | 1.53E-11 | Peripheral blood | Quiescent |  |
| LRRC75A.AS1 | 4.46E-01 | 2.57E-11 | Peripheral blood | Quiescent |  |
| FOXP1 | 3.25E-01 | $2.75 \mathrm{E}-11$ | Peripheral blood | Quiescent | $\bigcirc$ |
| S1PR1 | 5.11E-01 | 3.03E-11 | Peripheral blood | Quiescent | $\triangleleft$ |
| RPL26 | $3.76 \mathrm{E}-01$ | 3.69E-11 | Peripheral blood | Quiescent |  |
| RPS15A | 3.75E-01 | 6.71E-11 | Peripheral blood | Quiescent |  |
| RACK1 | 4.12E-01 | 7.37E-11 | Peripheral blood | Quiescent |  |
| RASGRP2 | 3.59E-01 | $1.32 \mathrm{E}-10$ | Peripheral blood | Quiescent |  |
| RPLP2 | 3.16E-01 | $1.32 \mathrm{E}-10$ | Peripheral blood | Quiescent |  |
| LRRC75A | $4.33 \mathrm{E}-01$ | $1.38 \mathrm{E}-10$ | Peripheral blood | Quiescent |  |
| TXNIP | $3.87 \mathrm{E}-01$ | $1.58 \mathrm{E}-10$ | Peripheral blood | Quiescent |  |
| PRKCA | 5.04E-01 | $2.38 \mathrm{E}-10$ | Peripheral blood | Quiescent | $\triangleleft$ |
| EIF4B | 3.07E-01 | $2.43 \mathrm{E}-10$ | Peripheral blood | Quiescent |  |
| RPL36 | $2.82 \mathrm{E}-01$ | 3.66E-10 | Peripheral blood | Quiescent |  |
| RPS27A | $2.80 \mathrm{E}-01$ | 5.51E-10 | Peripheral blood | Quiescent |  |
| LDLRAP1 | 4.77E-01 | 5.52E-10 | Peripheral blood | Quiescent |  |
| C1orf162 | 5.86E-01 | $1.04 \mathrm{E}-09$ | Peripheral blood | Quiescent |  |
| PIK3IP1 | 4.53E-01 | 2.67E-09 | Peripheral blood | Quiescent |  |
| DENND5A | $3.80 \mathrm{E}-01$ | $2.82 \mathrm{E}-09$ | Peripheral blood | Quiescent |  |
| ADTRP | 5.80E-01 | 5.46E-09 | Peripheral blood | Quiescent |  |
| RPL18 | 3.29E-01 | 8.19E-09 | Peripheral blood | Quiescent |  |
| RP4.635E18.8 | 3.91E-01 | $1.35 \mathrm{E}-08$ | Peripheral blood | Quiescent |  |
| RP11.252A24.7 | 3.79E-01 | $1.42 \mathrm{E}-08$ | Peripheral blood | Quiescent |  |
| RP11.458N5.1 | 3.88E-01 | $2.18 \mathrm{E}-08$ | Peripheral blood | Quiescent |  |
| GAS5 | 4.47E-01 | 2.20E-08 | Peripheral blood | Quiescent |  |
| MAL | 6.51E-01 | $2.91 \mathrm{E}-08$ | Peripheral blood | Quiescent |  |
| IL7R | 2.85E-01 | $4.34 \mathrm{E}-08$ | Peripheral blood | Quiescent |  |
| RPS23 | $3.36 \mathrm{E}-01$ | 7.98E-08 | Peripheral blood | Quiescent |  |
| RPL8 | $2.64 \mathrm{E}-01$ | $3.56 \mathrm{E}-07$ | Peripheral blood | Quiescent |  |
| PRKCQ.AS1 | 5.01E-01 | $3.81 \mathrm{E}-07$ | Peripheral blood | Quiescent |  |
| RPS9 | 3.11E-01 | $4.72 \mathrm{E}-07$ | Peripheral blood | Quiescent |  |
| NPM1 | 2.53E-01 | 7.45E-07 | Peripheral blood | Quiescent |  |
| TCEA3 | 4.72E-01 | 9.23E-07 | Peripheral blood | Quiescent |  |
| LINC01089 | 4.09E-01 | $9.79 \mathrm{E}-07$ | Peripheral blood | Quiescent |  |
| PRMT2 | $3.40 \mathrm{E}-01$ | 1.12E-06 | Peripheral blood | Quiescent |  |
| PFDN5 | 3.34E-01 | 1.18E-06 | Peripheral blood | Quiescent |  |


| Gene | Average log fold change | Adjusted p-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| RPL37 | $3.65 \mathrm{E}-01$ | 1.53E-06 | Peripheral blood | Quiescent |  |
| S100A8 | $5.75 \mathrm{E}-01$ | 1.86E-06 | Peripheral blood | Quiescent |  |
| RPLPO | $2.62 \mathrm{E}-01$ | 2.04E-06 | Peripheral blood | Quiescent |  |
| RPL12 | $3.16 \mathrm{E}-01$ | 2.10E-06 | Peripheral blood | Quiescent |  |
| FCN1 | 2.91E-01 | 2.36E-06 | Peripheral blood | Quiescent |  |
| PCED1B | 5.26E-01 | 2.38E-06 | Peripheral blood | Quiescent |  |
| RPL29 | $3.11 \mathrm{E}-01$ | 2.58E-06 | Peripheral blood | Quiescent |  |
| SVIL | $3.91 \mathrm{E}-01$ | 4.87E-06 | Peripheral blood | Quiescent |  |
| EEF1D | $2.92 \mathrm{E}-01$ | 5.91E-06 | Peripheral blood | Quiescent |  |
| SATB1 | $3.90 \mathrm{E}-01$ | $1.14 \mathrm{E}-05$ | Peripheral blood | Quiescent | - |
| ADD3 | $3.22 \mathrm{E}-01$ | 1.60E-05 | Peripheral blood | Quiescent |  |
| GIMAP4 | $3.17 \mathrm{E}-01$ | 2.26E-05 | Peripheral blood | Quiescent |  |
| GLTSCR2 | $3.43 \mathrm{E}-01$ | 2.58E-05 | Peripheral blood | Quiescent |  |
| SNORA12.2 | $3.27 \mathrm{E}-01$ | 2.65E-05 | Peripheral blood | Quiescent |  |
| RP11.434H6.7 | $4.19 \mathrm{E}-01$ | 5.27E-05 | Peripheral blood | Quiescent |  |
| CSF3R | $2.53 \mathrm{E}-01$ | 5.63E-05 | Peripheral blood | Quiescent | $\triangleleft$ |
| RASA3 | $4.09 \mathrm{E}-01$ | 7.03E-05 | Peripheral blood | Quiescent |  |
| RPL7A | $2.97 \mathrm{E}-01$ | 9.90E-05 | Peripheral blood | Quiescent |  |
| ZNF516 | $3.29 \mathrm{E}-01$ | 1.20E-04 | Peripheral blood | Quiescent | - |
| SUSD3 | $3.53 \mathrm{E}-01$ | 3.48E-04 | Peripheral blood | Quiescent |  |
| RPS4Y1 | $4.42 \mathrm{E}-01$ | 4.10E-04 | Peripheral blood | Quiescent |  |
| RPS4X | $2.59 \mathrm{E}-01$ | 4.95E-04 | Peripheral blood | Quiescent |  |
| ITGB2.AS1 | $2.82 \mathrm{E}-01$ | 5.50E-04 | Peripheral blood | Quiescent |  |
| SDK2 | $2.67 \mathrm{E}-01$ | $5.71 \mathrm{E}-04$ | Peripheral blood | Quiescent |  |
| IL16 | $2.61 \mathrm{E}-01$ | 6.35E-04 | Peripheral blood | Quiescent | * |
| LYZ | $5.78 \mathrm{E}-01$ | 8.54E-04 | Peripheral blood | Quiescent |  |
| RPS5 | $3.08 \mathrm{E}-01$ | 8.55E-04 | Peripheral blood | Quiescent |  |
| RPARP.AS1 | $3.44 \mathrm{E}-01$ | 8.77E-04 | Peripheral blood | Quiescent |  |
| RPL35A | $3.01 \mathrm{E}-01$ | 1.00E-03 | Peripheral blood | Quiescent |  |
| TXK | $3.42 \mathrm{E}-01$ | 1.03E-03 | Peripheral blood | Quiescent |  |
| DSEL | $4.16 \mathrm{E}-01$ | 2.31E-03 | Peripheral blood | Quiescent |  |
| S100A9 | 6.25E-01 | 2.32E-03 | Peripheral blood | Quiescent |  |
| SLC40A1 | $2.75 \mathrm{E}-01$ | 4.04E-03 | Peripheral blood | Quiescent |  |
| MORC2 | $3.33 \mathrm{E}-01$ | 4.93E-03 | Peripheral blood | Quiescent |  |
| SRSF5 | $3.26 \mathrm{E}-01$ | 5.69E-03 | Peripheral blood | Quiescent |  |
| BTF3 | $2.87 \mathrm{E}-01$ | 5.80E-03 | Peripheral blood | Quiescent |  |
| PCMTD2 | $2.96 \mathrm{E}-01$ | 6.22E-03 | Peripheral blood | Quiescent |  |
| TESPA1 | $3.02 \mathrm{E}-01$ | 7.20E-03 | Peripheral blood | Quiescent |  |
| SORL1 | $3.19 \mathrm{E}-01$ | 1.07E-02 | Peripheral blood | Quiescent |  |
| POLR3E | $2.65 \mathrm{E}-01$ | 1.11E-02 | Peripheral blood | Quiescent |  |


| Gene | Average log fold change | Adjusted p-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| VCAN | 2.53E-01 | 1.15E-02 | Peripheral blood | Quiescent |  |
| C10orf95 | $3.27 \mathrm{E}-01$ | 1.34E-02 | Peripheral blood | Quiescent |  |
| RPL22 | $2.75 \mathrm{E}-01$ | 1.50E-02 | Peripheral blood | Quiescent |  |
| ACTN1 | 2.98E-01 | 1.70E-02 | Peripheral blood | Quiescent |  |
| PIAS2 | $3.47 \mathrm{E}-01$ | 2.25E-02 | Peripheral blood | Quiescent |  |
| EXOSC8 | $3.22 \mathrm{E}-01$ | 2.48E-02 | Peripheral blood | Quiescent |  |
| BEX3 | 4.61E-01 | 2.52E-02 | Peripheral blood | Quiescent |  |
| SNHG8 | 4.14E-01 | 2.70E-02 | Peripheral blood | Quiescent |  |
| EIF3L | $2.74 \mathrm{E}-01$ | 3.56E-02 | Peripheral blood | Quiescent |  |
| FCGRT | 3.21E-01 | 4.16E-02 | Peripheral blood | Quiescent |  |
| REG1B | $1.84 \mathrm{E}+00$ | 5.02E-94 | Intestinal mucosa | REG1A/1B |  |
| REG1A | $2.11 \mathrm{E}+00$ | 3.79E-89 | Intestinal mucosa | REG1A/1B | * |
| PIGR | $1.88 \mathrm{E}+00$ | 6.63E-83 | Intestinal mucosa | REG1A/1B |  |
| ANPEP | 8.31E-01 | 2.25E-81 | Intestinal mucosa | REG1A/1B |  |
| DMBT1 | 9.04E-01 | 1.06E-76 | Intestinal mucosa | REG1A/1B |  |
| APOA1 | $8.54 \mathrm{E}-01$ | 9.13E-70 | Intestinal mucosa | REG1A/1B |  |
| APOC3 | 5.28E-01 | 1.40E-68 | Intestinal mucosa | REG1A/1B |  |
| PHGR1 | 7.82E-01 | 4.47E-57 | Intestinal mucosa | REG1A/1B |  |
| ALDOB | $1.17 \mathrm{E}+00$ | 1.55E-54 | Intestinal mucosa | REG1A/1B |  |
| SLC15A1 | 6.94E-01 | 1.22E-52 | Intestinal mucosa | REG1A/1B |  |
| FABP1 | $1.02 \mathrm{E}+00$ | 5.46E-50 | Intestinal mucosa | REG1A/1B |  |
| IFI27 | $3.57 \mathrm{E}-01$ | $3.94 \mathrm{E}-37$ | Intestinal mucosa | REG1A/1B |  |
| FABP6 | 3.47E-01 | 8.22E-37 | Intestinal mucosa | REG1A/1B |  |
| FABP2 | $5.56 \mathrm{E}-01$ | $1.69 \mathrm{E}-30$ | Intestinal mucosa | REG1A/1B |  |
| KRT19 | $3.51 \mathrm{E}-01$ | 2.18E-29 | Intestinal mucosa | REG1A/1B |  |
| LGALS4 | $4.02 \mathrm{E}-01$ | 2.97E-29 | Intestinal mucosa | REG1A/1B |  |
| SELENOP | $1.08 \mathrm{E}+00$ | 3.48E-29 | Intestinal mucosa | REG1A/1B |  |
| EPCAM | $3.57 \mathrm{E}-01$ | 8.27E-26 | Intestinal mucosa | REG1A/1B |  |
| TSPAN8 | $5.32 \mathrm{E}-01$ | 1.21E-25 | Intestinal mucosa | REG1A/1B |  |
| MUC13 | $3.14 \mathrm{E}-01$ | 6.08E-25 | Intestinal mucosa | REG1A/1B |  |
| $A P O B$ | $3.70 \mathrm{E}-01$ | 7.86E-24 | Intestinal mucosa | REG1A/1B |  |
| RARRES1 | $2.71 \mathrm{E}-01$ | 2.02E-23 | Intestinal mucosa | REG1A/1B |  |
| LGALS3BP | $4.42 \mathrm{E}-01$ | 8.21E-19 | Intestinal mucosa | REG1A/1B |  |
| HLA.DRA | $1.09 \mathrm{E}+00$ | 1.88E-17 | Intestinal mucosa | REG1A/1B |  |
| SMIM24 | 6.08E-01 | 4.88E-17 | Intestinal mucosa | REG1A/1B |  |
| SPINK1 | 5.47E-01 | 3.82E-14 | Intestinal mucosa | REG1A/1B |  |
| KRT8 | 3.29E-01 | 5.06E-14 | Intestinal mucosa | REG1A/1B |  |
| TFF3 | $2.89 \mathrm{E}-01$ | 3.91E-13 | Intestinal mucosa | REG1A/1B |  |
| HNF4A | 3.23E-01 | 1.43E-12 | Intestinal mucosa | REG1A/1B | - |
| AGR2 | $2.71 \mathrm{E}-01$ | 1.90E-12 | Intestinal mucosa | REG1A/1B |  |


| Gene | Average log fold change | Adjusted $p$-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| GOLIM4 | $2.80 \mathrm{E}-01$ | 5.38E-12 | Intestinal mucosa | REG1A/1B |  |
| KRT18 | $2.63 \mathrm{E}-01$ | 8.39E-11 | Intestinal mucosa | REG1A/1B |  |
| SLC6A19 | $2.66 \mathrm{E}-01$ | 2.33E-10 | Intestinal mucosa | REG1A/1B |  |
| HLA.DRB1 | 5.80E-01 | 2.24E-09 | Intestinal mucosa | REG1A/1B |  |
| CCDC152 | $3.27 \mathrm{E}-01$ | 2.65E-08 | Intestinal mucosa | REG1A/1B |  |
| ATP1B1 | $3.74 \mathrm{E}-01$ | 3.38E-08 | Intestinal mucosa | REG1A/1B |  |
| IGHA1 | $2.63 \mathrm{E}+00$ | 1.89E-06 | Intestinal mucosa | REG1A/1B |  |
| CD74 | $4.92 \mathrm{E}-01$ | 4.24E-06 | Intestinal mucosa | REG1A/1B |  |
| LGALS3 | 5.32E-01 | 4.52E-06 | Intestinal mucosa | REG1A/1B |  |
| ALDH2 | 3.23E-01 | 1.13E-05 | Intestinal mucosa | REG1A/1B |  |
| TSPAN3 | 7.87E-01 | 2.07E-05 | Intestinal mucosa | REG1A/1B |  |
| OAT | 4.68E-01 | 3.09E-05 | Intestinal mucosa | REG1A/1B |  |
| JCHAIN | $2.85 \mathrm{E}+00$ | 4.19E-05 | Intestinal mucosa | REG1A/1B |  |
| IGHG1 | $2.50 \mathrm{E}-01$ | 8.06E-05 | Intestinal mucosa | REG1A/1B |  |
| GCNT3 | $3.26 \mathrm{E}-01$ | 8.95E-05 | Intestinal mucosa | REG1A/1B |  |
| MS4A10 | $4.80 \mathrm{E}-01$ | 1.38E-04 | Intestinal mucosa | REG1A/1B |  |
| CST3 | $9.40 \mathrm{E}-01$ | 1.48E-04 | Intestinal mucosa | REG1A/1B |  |
| HLA.DPA1 | $3.73 \mathrm{E}-01$ | 6.53E-04 | Intestinal mucosa | REG1A/1B |  |
| ACO2 | $3.07 \mathrm{E}-01$ | 2.06E-03 | Intestinal mucosa | REG1A/1B |  |
| IGKC | $1.70 \mathrm{E}+00$ | 2.22E-03 | Intestinal mucosa | REG1A/1B |  |
| CTSD | 7.31E-01 | 2.28E-03 | Intestinal mucosa | REG1A/1B |  |
| TM9SF3 | $3.32 \mathrm{E}-01$ | 2.68E-03 | Intestinal mucosa | REG1A/1B |  |
| IGHA2 | $1.86 \mathrm{E}+00$ | 3.12E-03 | Intestinal mucosa | REG1A/1B |  |
| DDAH1 | $3.12 \mathrm{E}-01$ | $3.37 \mathrm{E}-03$ | Intestinal mucosa | REG1A/1B |  |
| RNF24 | $1.84 \mathrm{E}+00$ | $4.40 \mathrm{E}-03$ | Intestinal mucosa | REG1A/1B |  |
| ENAM | $2.07 \mathrm{E}+00$ | $4.78 \mathrm{E}-03$ | Intestinal mucosa | REG1A/1B |  |
| STK17B | 5.04E-01 | $1.02 \mathrm{E}-02$ | Intestinal mucosa | REG1A/1B |  |
| IGLC2 | $1.23 \mathrm{E}+00$ | 1.09E-02 | Intestinal mucosa | REG1A/1B |  |
| MUC2 | $2.75 \mathrm{E}-01$ | $1.14 \mathrm{E}-02$ | Intestinal mucosa | REG1A/1B |  |
| TAPBP | $5.61 \mathrm{E}-01$ | 1.88E-02 | Intestinal mucosa | REG1A/1B |  |
| ECHS1 | $6.72 \mathrm{E}-01$ | 2.22E-02 | Intestinal mucosa | REG1A/1B |  |
| OLFM4 | $4.49 \mathrm{E}-01$ | 4.22E-02 | Intestinal mucosa | REG1A/1B |  |
| RASGEF1B | $2.44 \mathrm{E}+00$ | 4.33E-294 | Intestinal mucosa | Th17 |  |
| RGS1 | $2.55 \mathrm{E}+00$ | 1.69E-247 | Intestinal mucosa | Th17 |  |
| CD69 | $2.36 \mathrm{E}+00$ | 1.04E-244 | Intestinal mucosa | Th17 |  |
| TNFAIP3 | $2.28 \mathrm{E}+00$ | 4.02E-237 | Intestinal mucosa | Th17 | $x$ |
| DUSP2 | $2.33 \mathrm{E}+00$ | 4.67E-186 | Intestinal mucosa | Th17 |  |
| DNAJB1 | $2.22 \mathrm{E}+00$ | 2.19E-184 | Intestinal mucosa | Th17 |  |
| MIR24.2 | $1.89 \mathrm{E}+00$ | 1.40E-150 | Intestinal mucosa | Th17 |  |
| NR4A2 | $1.93 \mathrm{E}+00$ | 4.10E-143 | Intestinal mucosa | Th17 | - |


| Gene | Average log fold change | Adjusted p-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| YPEL5 | $1.73 \mathrm{E}+00$ | 5.60E-142 | Intestinal mucosa | Th17 |  |
| FAM46C | $1.68 \mathrm{E}+00$ | 2.10E-106 | Intestinal mucosa | Th17 |  |
| PTGER4 | $1.67 \mathrm{E}+00$ | 1.15E-96 | Intestinal mucosa | Th17 | $x \triangleleft$ |
| SIK1 | 9.65E-01 | 8.05E-93 | Intestinal mucosa | Th17 |  |
| CYTIP | $1.16 \mathrm{E}+00$ | 1.35E-85 | Intestinal mucosa | Th17 |  |
| CXCR4 | $1.53 \mathrm{E}+00$ | 6.82E-79 | Intestinal mucosa | Th17 |  |
| SLC2A3 | $1.49 \mathrm{E}+00$ | 1.73E-78 | Intestinal mucosa | Th17 |  |
| HSP90AA1 | $1.33 \mathrm{E}+00$ | 5.06E-76 | Intestinal mucosa | Th17 |  |
| PHLDA1 | $1.63 \mathrm{E}+00$ | 3.02E-75 | Intestinal mucosa | Th17 |  |
| CREM | $1.33 \mathrm{E}+00$ | 4.48E-73 | Intestinal mucosa | Th17 | - |
| PFKFB3 | $1.26 \mathrm{E}+00$ | 5.93E-63 | Intestinal mucosa | Th17 |  |
| RGS2 | $1.69 \mathrm{E}+00$ | 8.00E-61 | Intestinal mucosa | Th17 |  |
| ZNF331 | $1.51 \mathrm{E}+00$ | 2.32E-60 | Intestinal mucosa | Th17 | - |
| DUSP5 | 7.63E-01 | 4.76E-57 | Intestinal mucosa | Th17 |  |
| TSC22D3 | $1.23 \mathrm{E}+00$ | 9.20E-56 | Intestinal mucosa | Th17 | - |
| CLEC2D | 7.86E-01 | 2.29E-55 | Intestinal mucosa | Th17 |  |
| SELENOK | $1.28 \mathrm{E}+00$ | 9.48E-55 | Intestinal mucosa | Th17 |  |
| CLK1 | 8.28E-01 | 3.30E-50 | Intestinal mucosa | Th17 |  |
| DUSP4 | $1.18 \mathrm{E}+00$ | $1.29 \mathrm{E}-48$ | Intestinal mucosa | Th17 |  |
| CSRNP1 | $1.14 \mathrm{E}+00$ | $1.89 \mathrm{E}-45$ | Intestinal mucosa | Th17 |  |
| PPP1CB | 7.14E-01 | 4.04E-45 | Intestinal mucosa | Th17 |  |
| PABPC1 | 8.12E-01 | 5.78E-44 | Intestinal mucosa | Th17 |  |
| SRGN | 8.04E-01 | 2.30E-43 | Intestinal mucosa | Th17 |  |
| HNRNPLL | $9.31 \mathrm{E}-01$ | $9.65 \mathrm{E}-43$ | Intestinal mucosa | Th17 |  |
| SPRY1 | $1.39 \mathrm{E}+00$ | $1.27 \mathrm{E}-42$ | Intestinal mucosa | Th17 |  |
| HSPH1 | $1.12 \mathrm{E}+00$ | 2.29E-39 | Intestinal mucosa | Th17 |  |
| KLF6 | 9.43E-01 | 1.80E-37 | Intestinal mucosa | Th17 | - |
| BIRC3 | $1.23 \mathrm{E}+00$ | 1.98E-37 | Intestinal mucosa | Th17 |  |
| FTH1 | $7.55 \mathrm{E}-01$ | 3.01E-37 | Intestinal mucosa | Th17 |  |
| PER1 | 8.30E-01 | 8.37E-37 | Intestinal mucosa | Th17 |  |
| MPZL3 | $1.05 \mathrm{E}+00$ | 7.70E-35 | Intestinal mucosa | Th17 |  |
| THBS1 | 6.66E-01 | 9.88E-34 | Intestinal mucosa | Th17 |  |
| KDM6B | 7.36E-01 | 3.01E-33 | Intestinal mucosa | Th17 |  |
| MORF4L2 | 7.79E-01 | 5.98E-33 | Intestinal mucosa | Th17 |  |
| ETF1 | 7.92E-01 | $2.71 \mathrm{E}-32$ | Intestinal mucosa | Th17 |  |
| DNAJA1 | $1.14 \mathrm{E}+00$ | 7.72E-31 | Intestinal mucosa | Th17 |  |
| CDKN1A | 8.15E-01 | $2.44 \mathrm{E}-30$ | Intestinal mucosa | Th17 |  |
| DNAJA4 | $1.24 \mathrm{E}+00$ | 6.98E-30 | Intestinal mucosa | Th17 |  |
| DUSP10 | 5.10E-01 | 1.84E-29 | Intestinal mucosa | Th17 |  |
| PDE4D | $1.04 \mathrm{E}+00$ | 2.66E-29 | Intestinal mucosa | Th17 | $\triangleleft$ |


| Gene | Average log fold change | Adjusted $p$-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| CD96 | $1.07 \mathrm{E}+00$ | 6.39E-28 | Intestinal mucosa | Th17 |  |
| LDLRAD4 | $1.20 \mathrm{E}+00$ | $1.35 \mathrm{E}-27$ | Intestinal mucosa | Th17 |  |
| USP36 | 9.61E-01 | 5.33E-27 | Intestinal mucosa | Th17 |  |
| STN1 | 7.47E-01 | 7.24E-27 | Intestinal mucosa | Th17 |  |
| RANBP2 | $6.00 \mathrm{E}-01$ | 2.00E-26 | Intestinal mucosa | Th17 |  |
| ABCA1 | $9.81 \mathrm{E}-01$ | 2.35E-26 | Intestinal mucosa | Th17 |  |
| SNORD99 | 6.28E-01 | 8.66E-26 | Intestinal mucosa | Th17 |  |
| KMT2E | $6.81 \mathrm{E}-01$ | 1.33E-25 | Intestinal mucosa | Th17 |  |
| ZFP36L2 | $7.49 \mathrm{E}-01$ | 1.82E-25 | Intestinal mucosa | Th17 | - |
| ZNF250 | $6.73 \mathrm{E}-01$ | 2.30E-25 | Intestinal mucosa | Th17 | - |
| ZSWIM4 | $4.11 \mathrm{E}-01$ | 2.35E-25 | Intestinal mucosa | Th17 |  |
| CCNH | $8.71 \mathrm{E}-01$ | 1.97E-24 | Intestinal mucosa | Th17 |  |
| BCAS2 | $1.00 \mathrm{E}+00$ | 4.49E-24 | Intestinal mucosa | Th17 |  |
| VMP1 | 6.84E-01 | 1.55E-23 | Intestinal mucosa | Th17 |  |
| EML4 | 8.37E-01 | 8.40E-23 | Intestinal mucosa | Th17 |  |
| MAPK1IP1L | $6.59 \mathrm{E}-01$ | 1.43E-22 | Intestinal mucosa | Th17 |  |
| ASB2 | $7.19 \mathrm{E}-01$ | 5.20E-22 | Intestinal mucosa | Th17 |  |
| CCL2O | 7.56E-01 | 5.46E-22 | Intestinal mucosa | Th17 | X* |
| PMAIP1 | $8.42 \mathrm{E}-01$ | 6.61E-22 | Intestinal mucosa | Th17 |  |
| IL22 | $1.00 \mathrm{E}+00$ | $4.75 \mathrm{E}-21$ | Intestinal mucosa | Th17 | * |
| NAMPT | $3.24 \mathrm{E}-01$ | 1.07E-20 | Intestinal mucosa | Th17 | * |
| SAT1 | 8.17E-01 | 2.65E-20 | Intestinal mucosa | Th17 |  |
| SDCBP | 9.11E-01 | 4.94E-20 | Intestinal mucosa | Th17 |  |
| RP11.138A9.2 | 6.81E-01 | $2.82 \mathrm{E}-19$ | Intestinal mucosa | Th17 |  |
| AC008440.5 | $2.64 \mathrm{E}-01$ | 3.08E-19 | Intestinal mucosa | Th17 |  |
| IRF2BP2 | $7.69 \mathrm{E}-01$ | 3.36E-19 | Intestinal mucosa | Th17 |  |
| SNHG16 | 7.47E-01 | 4.81E-19 | Intestinal mucosa | Th17 |  |
| CD55 | $7.44 \mathrm{E}-01$ | 1.47E-18 | Intestinal mucosa | Th17 |  |
| ARL5B | 7.57E-01 | 3.02E-18 | Intestinal mucosa | Th17 |  |
| ADAM19 | 5.04E-01 | 1.48E-17 | Intestinal mucosa | Th17 |  |
| RPL21 | $5.67 \mathrm{E}-01$ | 2.37E-17 | Intestinal mucosa | Th17 |  |
| PTP4A1 | $8.26 \mathrm{E}-01$ | 5.76E-17 | Intestinal mucosa | Th17 |  |
| MBOAT1 | 6.35E-01 | 1.28E-16 | Intestinal mucosa | Th17 |  |
| MAP3K8 | 8.01E-01 | 2.02E-16 | Intestinal mucosa | Th17 | $x$ |
| YWHAZ | $4.16 \mathrm{E}-01$ | 7.91E-16 | Intestinal mucosa | Th17 |  |
| EZR | $5.74 \mathrm{E}-01$ | $1.14 \mathrm{E}-15$ | Intestinal mucosa | Th17 |  |
| FMNL3 | $5.78 \mathrm{E}-01$ | 2.05E-15 | Intestinal mucosa | Th17 |  |
| IFRD1 | 7.10E-01 | 3.02E-15 | Intestinal mucosa | Th17 |  |
| PDCD4 | $4.13 \mathrm{E}-01$ | 3.12E-15 | Intestinal mucosa | Th17 |  |
| CCL5 | $4.99 \mathrm{E}-01$ | 4.01E-15 | Intestinal mucosa | Th17 | * |


| Gene | Average log fold change | Adjusted p-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| HSP90AB1 | $7.36 \mathrm{E}-01$ | 1.22E-14 | Intestinal mucosa | Th17 |  |
| ICOS | $8.82 \mathrm{E}-01$ | 2.59E-14 | Intestinal mucosa | Th17 |  |
| PRMT9 | $8.69 \mathrm{E}-01$ | 5.56E-14 | Intestinal mucosa | Th17 |  |
| STAT1 | $6.65 \mathrm{E}-01$ | 2.33E-13 | Intestinal mucosa | Th17 | - |
| PIM3 | 7.52E-01 | 3.22E-13 | Intestinal mucosa | Th17 |  |
| PPP1R15B | $5.32 \mathrm{E}-01$ | 4.10E-12 | Intestinal mucosa | Th17 |  |
| IL17A | $1.04 \mathrm{E}+00$ | 1.10E-11 | Intestinal mucosa | Th17 | * $\triangleleft$ |
| VPS37B | $4.82 \mathrm{E}-01$ | 1.29E-11 | Intestinal mucosa | Th17 |  |
| HSPE1 | $9.28 \mathrm{E}-01$ | 1.33E-11 | Intestinal mucosa | Th17 |  |
| IRF4 | 5.31E-01 | 2.02E-11 | Intestinal mucosa | Th17 | $x$ - |
| RORA | $6.06 \mathrm{E}-01$ | 2.80E-11 | Intestinal mucosa | Th17 | $\bigcirc$ |
| NFE2L2 | $7.10 \mathrm{E}-01$ | 3.08E-11 | Intestinal mucosa | Th17 | $\bullet$ |
| IFNG | 7.86E-01 | 5.22E-11 | Intestinal mucosa | Th17 | X* |
| HLA.J | $3.67 \mathrm{E}-01$ | 6.82E-11 | Intestinal mucosa | Th17 |  |
| HSPA8 | $5.68 \mathrm{E}-01$ | 8.03E-11 | Intestinal mucosa | Th17 |  |
| TSPYL1 | $4.34 \mathrm{E}-01$ | 8.10E-11 | Intestinal mucosa | Th17 |  |
| AHSA1 | 3.97E-01 | 1.21E-10 | Intestinal mucosa | Th17 |  |
| NUP98 | $4.89 \mathrm{E}-01$ | 1.43E-10 | Intestinal mucosa | Th17 |  |
| SRSF3 | $4.46 \mathrm{E}-01$ | 1.91E-10 | Intestinal mucosa | Th17 |  |
| CHD1 | 6.84E-01 | 2.29E-10 | Intestinal mucosa | Th17 | - |
| LINC.PINT | $4.89 \mathrm{E}-01$ | 3.95E-10 | Intestinal mucosa | Th17 |  |
| RP11.631M6.2 | $3.95 \mathrm{E}-01$ | 1.55E-09 | Intestinal mucosa | Th17 |  |
| ANKHD1 | 6.47E-01 | 1.71E-09 | Intestinal mucosa | Th17 |  |
| SNHG12 | $2.86 \mathrm{E}-01$ | 3.06E-09 | Intestinal mucosa | Th17 |  |
| CLDND1 | $6.63 \mathrm{E}-01$ | 1.45E-08 | Intestinal mucosa | Th17 |  |
| TSC22D2 | $4.38 \mathrm{E}-01$ | 2.21E-08 | Intestinal mucosa | Th17 | - |
| ISG15 | $6.10 \mathrm{E}-01$ | 2.42E-08 | Intestinal mucosa | Th17 |  |
| PTPN22 | $4.53 \mathrm{E}-01$ | 3.13E-08 | Intestinal mucosa | Th17 | $x$ |
| TP53INP1 | $5.00 \mathrm{E}-01$ | 1.56E-07 | Intestinal mucosa | Th17 |  |
| CHD2 | $5.33 \mathrm{E}-01$ | 1.87E-07 | Intestinal mucosa | Th17 | - |
| HES4 | $3.99 \mathrm{E}-01$ | 1.99E-07 | Intestinal mucosa | Th17 | - |
| RP11.138A9.1 | 5.05E-01 | 2.49E-07 | Intestinal mucosa | Th17 |  |
| GNL3 | $5.16 \mathrm{E}-01$ | 2.71E-07 | Intestinal mucosa | Th17 |  |
| AC092580.4 | $4.92 \mathrm{E}-01$ | 3.48E-07 | Intestinal mucosa | Th17 |  |
| DNAJB4 | $4.84 \mathrm{E}-01$ | $4.24 \mathrm{E}-07$ | Intestinal mucosa | Th17 | $x$ |
| GFPT2 | $3.76 \mathrm{E}-01$ | 4.30E-07 | Intestinal mucosa | Th17 |  |
| TIPARP | 7.20E-01 | 4.66E-07 | Intestinal mucosa | Th17 | - |
| DHX36 | $4.05 \mathrm{E}-01$ | 6.87E-07 | Intestinal mucosa | Th17 |  |
| CYCS | $8.36 \mathrm{E}-01$ | 7.24E-07 | Intestinal mucosa | Th17 |  |
| PTGES3 | $5.18 \mathrm{E}-01$ | 9.72E-07 | Intestinal mucosa | Th17 |  |


| Gene | Average log fold change | Adjusted p-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| STRN3 | $4.36 \mathrm{E}-01$ | 3.24E-06 | Intestinal mucosa | Th17 |  |
| LRRC1 | $4.00 \mathrm{E}-01$ | 4.56E-06 | Intestinal mucosa | Th17 |  |
| PTBP2 | 3.99E-01 | 6.32E-06 | Intestinal mucosa | Th17 |  |
| UBE2B | $3.62 \mathrm{E}-01$ | 6.48E-06 | Intestinal mucosa | Th17 |  |
| ARHGEF7 | $4.56 \mathrm{E}-01$ | 7.35E-06 | Intestinal mucosa | Th17 |  |
| RP11.727F15.9 | 5.28E-01 | 7.46E-06 | Intestinal mucosa | Th17 |  |
| RHOH | $4.87 \mathrm{E}-01$ | 7.91E-06 | Intestinal mucosa | Th17 |  |
| LDLR | $4.20 \mathrm{E}-01$ | 8.22E-06 | Intestinal mucosa | Th17 |  |
| ZBTB10 | $4.10 \mathrm{E}-01$ | 9.07E-06 | Intestinal mucosa | Th17 | - |
| CTB.131B5.2 | 3.62E-01 | 9.32E-06 | Intestinal mucosa | Th17 |  |
| H3F3B | 4.60E-01 | 9.46E-06 | Intestinal mucosa | Th17 |  |
| DEFA5 | 2.99E-01 | 1.04E-05 | Intestinal mucosa | Th17 | * |
| TANK | $4.51 \mathrm{E}-01$ | 1.06E-05 | Intestinal mucosa | Th17 |  |
| ERN1 | 5.39E-01 | 1.32E-05 | Intestinal mucosa | Th17 |  |
| ZBTB25 | $4.18 \mathrm{E}-01$ | 1.56E-05 | Intestinal mucosa | Th17 | - |
| HECA | 5.08E-01 | 1.56E-05 | Intestinal mucosa | Th17 |  |
| NOP58 | 3.89E-01 | 1.58E-05 | Intestinal mucosa | Th17 |  |
| NASP | 3.57E-01 | 2.40E-05 | Intestinal mucosa | Th17 |  |
| GPR34 | 5.99E-01 | 2.73E-05 | Intestinal mucosa | Th17 |  |
| DOCK11 | 4.54E-01 | 2.83E-05 | Intestinal mucosa | Th17 |  |
| SYTL3 | 7.15E-01 | 2.99E-05 | Intestinal mucosa | Th17 |  |
| RP11.297H3.3 | 6.31E-01 | $3.56 \mathrm{E}-05$ | Intestinal mucosa | Th17 |  |
| CCL4 | 9.08E-01 | $3.66 \mathrm{E}-05$ | Intestinal mucosa | Th17 | * |
| TSPYL2 | 7.38E-01 | $3.93 \mathrm{E}-05$ | Intestinal mucosa | Th17 |  |
| WDR74 | 3.58E-01 | 5.73E-05 | Intestinal mucosa | Th17 |  |
| CHMP1B | $5.35 \mathrm{E}-01$ | 6.03E-05 | Intestinal mucosa | Th17 |  |
| STRAP | $4.98 \mathrm{E}-01$ | 7.87E-05 | Intestinal mucosa | Th17 |  |
| OSTF1 | $3.75 \mathrm{E}-01$ | 9.02E-05 | Intestinal mucosa | Th17 |  |
| CTD.2636A23.2 | 2.54E-01 | 1.43E-04 | Intestinal mucosa | Th17 |  |
| LZTFL1 | 3.36E-01 | 1.60E-04 | Intestinal mucosa | Th17 |  |
| KLRB1 | $5.69 \mathrm{E}-01$ | 2.27E-04 | Intestinal mucosa | Th17 |  |
| SH2D2A | $5.69 \mathrm{E}-01$ | 2.63E-04 | Intestinal mucosa | Th17 |  |
| SHISA2 | 4.90E-01 | 2.78E-04 | Intestinal mucosa | Th17 |  |
| DDX3X | 3.11E-01 | 2.81E-04 | Intestinal mucosa | Th17 |  |
| HSPA6 | $4.77 \mathrm{E}-01$ | 3.12E-04 | Intestinal mucosa | Th17 |  |
| STIP1 | $4.22 \mathrm{E}-01$ | 3.50E-04 | Intestinal mucosa | Th17 |  |
| PIK3R1 | 7.36E-01 | 3.53E-04 | Intestinal mucosa | Th17 |  |
| ETV3 | $4.55 \mathrm{E}-01$ | 4.25E-04 | Intestinal mucosa | Th17 | - |
| ZNF267 | $4.35 \mathrm{E}-01$ | 4.54E-04 | Intestinal mucosa | Th17 | - |
| UBB | 4.68E-01 | 6.99E-04 | Intestinal mucosa | Th17 |  |


| Gene | Average log fold change | Adjusted $p$-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| CFAP20 | 6.38E-01 | 8.83E-04 | Intestinal mucosa | Th17 |  |
| G3BP2 | 4.94E-01 | 9.43E-04 | Intestinal mucosa | Th17 |  |
| ZC3H12A | 5.09E-01 | 9.88E-04 | Intestinal mucosa | Th17 |  |
| ITGA1 | 7.52E-01 | $1.24 \mathrm{E}-03$ | Intestinal mucosa | Th17 |  |
| RP3.370M22.8 | 4.11E-01 | 1.26E-03 | Intestinal mucosa | Th17 |  |
| PPP3CA | 3.55E-01 | $1.69 \mathrm{E}-03$ | Intestinal mucosa | Th17 |  |
| AUTS2 | 3.08E-01 | $1.73 \mathrm{E}-03$ | Intestinal mucosa | Th17 |  |
| SOCS1 | 6.59E-01 | $1.78 \mathrm{E}-03$ | Intestinal mucosa | Th17 | $x$ |
| CEBPZ | 2.89E-01 | 2.43E-03 | Intestinal mucosa | Th17 | - |
| REL | 3.88E-01 | 4.08E-03 | Intestinal mucosa | Th17 | X |
| FAM177A1 | $5.57 \mathrm{E}-01$ | 4.57E-03 | Intestinal mucosa | Th17 |  |
| TAGAP | 5.94E-01 | 6.05E-03 | Intestinal mucosa | Th17 | $x$ |
| RNF19A | 3.25E-01 | 9.96E-03 | Intestinal mucosa | Th17 |  |
| GABARAPL1 | 3.19E-01 | 1.02E-02 | Intestinal mucosa | Th17 |  |
| NABP1 | $2.73 \mathrm{E}-01$ | 1.16E-02 | Intestinal mucosa | Th17 |  |
| GALK2 | 4.63E-01 | 1.18E-02 | Intestinal mucosa | Th17 |  |
| BTG3 | 5.26E-01 | 1.40E-02 | Intestinal mucosa | Th17 |  |
| COCH | 2.63E-01 | 1.64E-02 | Intestinal mucosa | Th17 |  |
| ZFP36L1 | $3.82 \mathrm{E}-01$ | 2.02E-02 | Intestinal mucosa | Th17 | x |
| DCTN6 | 3.41E-01 | 2.20E-02 | Intestinal mucosa | Th17 |  |
| PAPOLA | 5.16E-01 | 2.39E-02 | Intestinal mucosa | Th17 |  |
| IL2 | 3.81E-01 | 2.59E-02 | Intestinal mucosa | Th17 | * |
| ZC3H12D | 3.08E-01 | $2.74 \mathrm{E}-02$ | Intestinal mucosa | Th17 |  |
| KPNA2 | 4.57E-01 | $3.42 \mathrm{E}-02$ | Intestinal mucosa | Th17 |  |
| GPR35 | $2.99 \mathrm{E}-01$ | $3.68 \mathrm{E}-02$ | Intestinal mucosa | Th17 |  |
| ARL4D | $4.03 \mathrm{E}-01$ | $4.22 \mathrm{E}-02$ | Intestinal mucosa | Th17 |  |
| NUP58 | $4.79 \mathrm{E}-01$ | 4.40E-02 | Intestinal mucosa | Th17 |  |
| S100A4 | 6.18E-01 | 3.44E-67 | Peripheral blood | Effector/Treg |  |
| LTB | 7.50E-01 | 6.76E-62 | Peripheral blood | Effector/Treg | * |
| TOB1 | 5.29E-01 | 8.63E-45 | Peripheral blood | Effector/Treg |  |
| C16orf54 | $3.13 \mathrm{E}-01$ | 7.21E-43 | Peripheral blood | Effector/Treg |  |
| CD52 | $4.09 \mathrm{E}-01$ | 2.02E-41 | Peripheral blood | Effector/Treg |  |
| IL32 | $3.94 \mathrm{E}-01$ | 2.07E-39 | Peripheral blood | Effector/Treg | * |
| TMSB10 | 3.63E-01 | 3.36E-36 | Peripheral blood | Effector/Treg |  |
| EMP3 | $2.58 \mathrm{E}-01$ | 2.64E-33 | Peripheral blood | Effector/Treg |  |
| TNFRSF25 | 3.83E-01 | 2.37E-29 | Peripheral blood | Effector/Treg |  |
| RAP2B | 3.64E-01 | 2.35E-28 | Peripheral blood | Effector/Treg |  |
| RASSF3 | $2.66 \mathrm{E}-01$ | 2.52E-28 | Peripheral blood | Effector/Treg |  |
| S100A11 | 4.07E-01 | 4.78E-25 | Peripheral blood | Effector/Treg |  |
| PRDM1 | 3.98E-01 | 1.43E-24 | Peripheral blood | Effector/Treg | $x$ - |


| Gene | Average log fold change | Adjusted p-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| CALM1 | 2.96E-01 | 1.48E-24 | Peripheral blood | Effector/Treg |  |
| RPL13A | 3.30E-01 | 6.10E-24 | Peripheral blood | Effector/Treg |  |
| TTC39C | $2.73 \mathrm{E}-01$ | 9.43E-23 | Peripheral blood | Effector/Treg |  |
| RUNX2 | 6.60E-01 | 8.29E-22 | Peripheral blood | Effector/Treg | - |
| ADAM19 | $3.99 \mathrm{E}-01$ | 1.67E-21 | Peripheral blood | Effector/Treg |  |
| FAM65B | $3.16 \mathrm{E}-01$ | 2.22E-21 | Peripheral blood | Effector/Treg |  |
| SH3BGRL3 | $3.48 \mathrm{E}-01$ | 1.02E-19 | Peripheral blood | Effector/Treg |  |
| AES | $2.73 \mathrm{E}-01$ | 1.75E-18 | Peripheral blood | Effector/Treg |  |
| TTC39C.AS1 | 4.49E-01 | 1.21E-17 | Peripheral blood | Effector/Treg |  |
| FLNA | $4.53 \mathrm{E}-01$ | 6.53E-17 | Peripheral blood | Effector/Treg |  |
| FUT7 | $3.14 \mathrm{E}-01$ | 2.06E-16 | Peripheral blood | Effector/Treg |  |
| SOCS2 | 6.58E-01 | 2.85E-16 | Peripheral blood | Effector/Treg |  |
| PIM1 | 5.37E-01 | 2.92E-16 | Peripheral blood | Effector/Treg |  |
| MORC2.AS1 | $3.79 \mathrm{E}-01$ | 3.47E-16 | Peripheral blood | Effector/Treg |  |
| PSME1 | 2.80E-01 | 1.42E-15 | Peripheral blood | Effector/Treg |  |
| MORC2 | $4.93 \mathrm{E}-01$ | 8.75E-15 | Peripheral blood | Effector/Treg |  |
| TESPA1 | $3.74 \mathrm{E}-01$ | 1.36E-14 | Peripheral blood | Effector/Treg |  |
| RPL5 | 2.80E-01 | 6.17E-14 | Peripheral blood | Effector/Treg |  |
| PCED1B.AS1 | 2.70E-01 | 9.66E-14 | Peripheral blood | Effector/Treg |  |
| PLP2 | 5.98E-01 | 1.38E-13 | Peripheral blood | Effector/Treg |  |
| PTPN13 | $4.66 \mathrm{E}-01$ | $1.47 \mathrm{E}-13$ | Peripheral blood | Effector/Treg |  |
| CMTM6 | $4.78 \mathrm{E}-01$ | 1.93E-13 | Peripheral blood | Effector/Treg | * |
| S1PR1 | 4.97E-01 | 2.43E-13 | Peripheral blood | Effector/Treg | $\triangleleft$ |
| RPLPO | 2.57E-01 | $2.75 \mathrm{E}-13$ | Peripheral blood | Effector/Treg |  |
| TNFRSF4 | $4.85 \mathrm{E}-01$ | 8.03E-13 | Peripheral blood | Effector/Treg | $x$ |
| ANXA2 | $4.32 \mathrm{E}-01$ | 9.76E-13 | Peripheral blood | Effector/Treg |  |
| S100A10 | 5.28E-01 | 1.29E-12 | Peripheral blood | Effector/Treg |  |
| CTSH | $5.95 \mathrm{E}-01$ | 1.98E-12 | Peripheral blood | Effector/Treg |  |
| P2RY8 | $4.81 \mathrm{E}-01$ | $2.34 \mathrm{E}-12$ | Peripheral blood | Effector/Treg |  |
| BIN2 | $4.23 \mathrm{E}-01$ | 4.11E-12 | Peripheral blood | Effector/Treg |  |
| C21orf33 | $2.61 \mathrm{E}-01$ | 4.25E-12 | Peripheral blood | Effector/Treg |  |
| SLC25A6 | $3.23 \mathrm{E}-01$ | 5.05E-12 | Peripheral blood | Effector/Treg |  |
| NOSIP | $6.04 \mathrm{E}-01$ | 5.06E-12 | Peripheral blood | Effector/Treg |  |
| USP10 | $5.74 \mathrm{E}-01$ | 3.09E-11 | Peripheral blood | Effector/Treg |  |
| TSPO | 6.49E-01 | 3.11E-11 | Peripheral blood | Effector/Treg |  |
| IL7R | $2.83 \mathrm{E}-01$ | 4.13E-11 | Peripheral blood | Effector/Treg |  |
| RPL4 | $2.84 \mathrm{E}-01$ | 9.82E-11 | Peripheral blood | Effector/Treg |  |
| TIMP1 | 5.64E-01 | 1.13E-10 | Peripheral blood | Effector/Treg |  |
| NPDC1 | 3.83E-01 | 1.38E-10 | Peripheral blood | Effector/Treg |  |
| SELPLG | $4.92 \mathrm{E}-01$ | 1.73E-10 | Peripheral blood | Effector/Treg |  |


| Gene | Average log fold change | Adjusted p-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| RPL18 | 2.56E-01 | 1.28E-09 | Peripheral blood | Effector/Treg |  |
| TRAT1 | $4.50 \mathrm{E}-01$ | 1.38E-09 | Peripheral blood | Effector/Treg |  |
| MAP3K1 | 5.20E-01 | 3.08E-09 | Peripheral blood | Effector/Treg |  |
| CAPN2 | $4.85 \mathrm{E}-01$ | 5.43E-09 | Peripheral blood | Effector/Treg |  |
| GBP5 | $4.51 \mathrm{E}-01$ | 1.05E-08 | Peripheral blood | Effector/Treg |  |
| SVIL | $4.19 \mathrm{E}-01$ | 1.16E-08 | Peripheral blood | Effector/Treg |  |
| HSD11B1 | 3.86E-01 | 1.33E-08 | Peripheral blood | Effector/Treg |  |
| AQP3 | $4.76 \mathrm{E}-01$ | $1.77 \mathrm{E}-08$ | Peripheral blood | Effector/Treg |  |
| CDC25B | 3.66E-01 | 4.66E-08 | Peripheral blood | Effector/Treg |  |
| GTF3A | $4.03 \mathrm{E}-01$ | 5.53E-08 | Peripheral blood | Effector/Treg | - |
| C12orf75 | 6.12E-01 | 7.35E-08 | Peripheral blood | Effector/Treg |  |
| CISH | 5.24E-01 | 8.45E-08 | Peripheral blood | Effector/Treg |  |
| GLUL | 5.11E-01 | 9.62E-08 | Peripheral blood | Effector/Treg |  |
| MFNG | $3.79 \mathrm{E}-01$ | 1.26E-07 | Peripheral blood | Effector/Treg |  |
| PDIA4 | 2.81E-01 | 2.34E-07 | Peripheral blood | Effector/Treg |  |
| LDHB | $2.59 \mathrm{E}-01$ | 2.97E-07 | Peripheral blood | Effector/Treg |  |
| RP11.356J5.12 | 5.69E-01 | 3.68E-07 | Peripheral blood | Effector/Treg |  |
| ILIORA | $3.29 \mathrm{E}-01$ | 6.00E-07 | Peripheral blood | Effector/Treg |  |
| ARPC1B | 2.70E-01 | 6.26E-07 | Peripheral blood | Effector/Treg |  |
| ITGB2 | $2.74 \mathrm{E}-01$ | 7.35E-07 | Peripheral blood | Effector/Treg |  |
| PDCD5 | 5.30E-01 | 7.94E-07 | Peripheral blood | Effector/Treg |  |
| SLC40A1 | 3.77E-01 | $8.32 \mathrm{E}-07$ | Peripheral blood | Effector/Treg |  |
| YWHAQ | $2.85 \mathrm{E}-01$ | 2.17E-06 | Peripheral blood | Effector/Treg |  |
| ELK3 | 4.46E-01 | $2.71 \mathrm{E}-06$ | Peripheral blood | Effector/Treg | - |
| NECAP2 | $4.12 \mathrm{E}-01$ | 3.59E-06 | Peripheral blood | Effector/Treg |  |
| ELOVL4 | $3.71 \mathrm{E}-01$ | 4.33E-06 | Peripheral blood | Effector/Treg |  |
| MOSPD3 | $3.37 \mathrm{E}-01$ | 5.23E-06 | Peripheral blood | Effector/Treg |  |
| PSMB8 | $3.76 \mathrm{E}-01$ | 5.97E-06 | Peripheral blood | Effector/Treg |  |
| TRADD | $4.01 \mathrm{E}-01$ | 7.02E-06 | Peripheral blood | Effector/Treg |  |
| SSR4 | 2.66E-01 | 2.17E-05 | Peripheral blood | Effector/Treg |  |
| TXN | $3.24 \mathrm{E}-01$ | 2.26E-05 | Peripheral blood | Effector/Treg |  |
| MYC | $4.04 \mathrm{E}-01$ | 3.83E-05 | Peripheral blood | Effector/Treg | - |
| TEX264 | 5.62E-01 | 1.17E-04 | Peripheral blood | Effector/Treg |  |
| JAKMIP1 | $2.71 \mathrm{E}-01$ | 1.18E-04 | Peripheral blood | Effector/Treg |  |
| RNASET2 | $3.30 \mathrm{E}-01$ | $1.27 \mathrm{E}-04$ | Peripheral blood | Effector/Treg | $x$ |
| LTK | $2.74 \mathrm{E}-01$ | $1.67 \mathrm{E}-04$ | Peripheral blood | Effector/Treg |  |
| PLEKHG3 | $2.65 \mathrm{E}-01$ | 1.74E-04 | Peripheral blood | Effector/Treg |  |
| CNN2 | 2.68E-01 | 1.76E-04 | Peripheral blood | Effector/Treg |  |
| MT.TT | 2.81E-01 | 2.00E-04 | Peripheral blood | Effector/Treg |  |
| AHNAK | 2.84E-01 | 2.01E-04 | Peripheral blood | Effector/Treg |  |


| Gene | Average log fold change | Adjusted p-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| BIN1 | $3.85 \mathrm{E}-01$ | 2.25E-04 | Peripheral blood | Effector/Treg |  |
| C10orf54 | $4.48 \mathrm{E}-01$ | 2.46E-04 | Peripheral blood | Effector/Treg |  |
| REXO2 | $3.75 \mathrm{E}-01$ | 3.66E-04 | Peripheral blood | Effector/Treg |  |
| TC2N | 3.17E-01 | 4.28E-04 | Peripheral blood | Effector/Treg |  |
| DPP4 | 2.50E-01 | 5.66E-04 | Peripheral blood | Effector/Treg |  |
| ENO1 | 3.00E-01 | 6.73E-04 | Peripheral blood | Effector/Treg |  |
| NSG1 | $3.90 \mathrm{E}-01$ | 7.02E-04 | Peripheral blood | Effector/Treg |  |
| HINT1 | 2.60E-01 | 7.02E-04 | Peripheral blood | Effector/Treg |  |
| SIT1 | $3.32 \mathrm{E}-01$ | 1.78E-03 | Peripheral blood | Effector/Treg |  |
| TRAF3IP3 | $2.91 \mathrm{E}-01$ | 2.04E-03 | Peripheral blood | Effector/Treg |  |
| SEC61B | $2.59 \mathrm{E}-01$ | 2.44E-03 | Peripheral blood | Effector/Treg |  |
| CCR2 | $2.93 \mathrm{E}-01$ | 2.56E-03 | Peripheral blood | Effector/Treg | $x$ |
| ICAM2 | $4.66 \mathrm{E}-01$ | 3.01E-03 | Peripheral blood | Effector/Treg |  |
| ATP5F1 | $2.98 \mathrm{E}-01$ | 5.84E-03 | Peripheral blood | Effector/Treg |  |
| RIPK2 | $4.75 \mathrm{E}-01$ | 6.17E-03 | Peripheral blood | Effector/Treg | $x$ |
| CBLL1 | $3.34 \mathrm{E}-01$ | 6.32E-03 | Peripheral blood | Effector/Treg | - |
| LRRFIP1 | $2.80 \mathrm{E}-01$ | 6.58E-03 | Peripheral blood | Effector/Treg |  |
| S1PR4 | $3.74 \mathrm{E}-01$ | 7.70E-03 | Peripheral blood | Effector/Treg | $\triangleleft$ |
| EIF4EBP2 | 2.69E-01 | 8.50E-03 | Peripheral blood | Effector/Treg |  |
| CPT1A | $2.54 \mathrm{E}-01$ | 9.14E-03 | Peripheral blood | Effector/Treg |  |
| SYTL1 | $2.86 \mathrm{E}-01$ | 1.06E-02 | Peripheral blood | Effector/Treg |  |
| SLIRP | $3.02 \mathrm{E}-01$ | 1.25E-02 | Peripheral blood | Effector/Treg |  |
| TNFAIP8 | $2.91 \mathrm{E}-01$ | 1.29E-02 | Peripheral blood | Effector/Treg |  |
| RSU1 | $3.85 \mathrm{E}-01$ | $1.64 \mathrm{E}-02$ | Peripheral blood | Effector/Treg |  |
| ARL14EP | $2.70 \mathrm{E}-01$ | 1.79E-02 | Peripheral blood | Effector/Treg |  |
| CYTH1 | $2.57 \mathrm{E}-01$ | 1.90E-02 | Peripheral blood | Effector/Treg |  |
| MAT2B | $3.02 \mathrm{E}-01$ | 2.12E-02 | Peripheral blood | Effector/Treg |  |
| LPAR6 | $3.77 \mathrm{E}-01$ | 2.42E-02 | Peripheral blood | Effector/Treg |  |
| EAF1 | $2.78 \mathrm{E}-01$ | 2.58E-02 | Peripheral blood | Effector/Treg |  |
| CARD16 | $3.12 \mathrm{E}-01$ | 2.76E-02 | Peripheral blood | Effector/Treg |  |
| SMDT1 | 2.67E-01 | 3.69E-02 | Peripheral blood | Effector/Treg |  |
| MYO1F | $3.07 \mathrm{E}-01$ | 4.61E-02 | Peripheral blood | Effector/Treg |  |
| CDC42SE1 | $9.05 \mathrm{E}-01$ | 8.32E-44 | Peripheral blood | Treg/Quiescent |  |
| C1orf56 | $9.03 \mathrm{E}-01$ | 3.44E-42 | Peripheral blood | Treg/Quiescent |  |
| HNRNPH1 | 7.20E-01 | 1.88E-37 | Peripheral blood | Treg/Quiescent |  |
| MTA2 | 6.33E-01 | 1.15E-12 | Peripheral blood | Treg/Quiescent | - |
| C16orf54 | $7.99 \mathrm{E}-01$ | 8.09E-12 | Peripheral blood | Treg/Quiescent |  |
| HNRNPL | 5.86E-01 | 2.67E-11 | Peripheral blood | Treg/Quiescent |  |
| SRSF6 | 5.83E-01 | 2.37E-07 | Peripheral blood | Treg/Quiescent |  |
| RASSF3 | $8.64 \mathrm{E}-01$ | 4.41E-07 | Peripheral blood | Treg/Quiescent |  |


| Gene | Average log fold change | Adjusted p-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| EIF5A | 4.91E-01 | 1.62E-06 | Peripheral blood | Treg/Quiescent |  |
| CTNNB1 | 5.27E-01 | 7.67E-06 | Peripheral blood | Treg/Quiescent |  |
| CTBP1 | 7.36E-01 | 3.51E-05 | Peripheral blood | Treg/Quiescent |  |
| SAR1A | $3.91 \mathrm{E}-01$ | 4.35E-05 | Peripheral blood | Treg/Quiescent |  |
| MPRIP | 8.35E-01 | 4.67E-04 | Peripheral blood | Treg/Quiescent |  |
| GIGYF1 | 6.07E-01 | 6.64E-04 | Peripheral blood | Treg/Quiescent |  |
| PCBP2 | $4.81 \mathrm{E}-01$ | $1.06 \mathrm{E}-03$ | Peripheral blood | Treg/Quiescent |  |
| POLR2J3 | 4.20E-01 | $1.43 \mathrm{E}-03$ | Peripheral blood | Treg/Quiescent |  |
| B4GALT1 | 4.09E-01 | 6.54E-03 | Peripheral blood | Treg/Quiescent |  |
| RAB12 | 7.70E-01 | 7.50E-03 | Peripheral blood | Treg/Quiescent |  |
| WTAP | $4.85 \mathrm{E}-01$ | $2.68 \mathrm{E}-02$ | Peripheral blood | Treg/Quiescent |  |
| C6orf62 | $4.52 \mathrm{E}-01$ | 3.14E-02 | Peripheral blood | Treg/Quiescent |  |
| NOG | $9.18 \mathrm{E}-01$ | 3.82E-02 | Peripheral blood | Treg/Quiescent |  |
| FLVCR2 | 6.93E-01 | 4.00E-96 | Intestinal mucosa | Treg/Quiescent |  |
| SYT8 | 7.73E-01 | 2.91E-54 | Intestinal mucosa | Treg/Quiescent |  |
| MTND4P12 | 6.81E-01 | 1.20E-43 | Intestinal mucosa | Treg/Quiescent |  |
| CXCR5 | $1.02 \mathrm{E}+00$ | 2.40E-35 | Intestinal mucosa | Treg/Quiescent | $x$ |
| ICA1 | $8.77 \mathrm{E}-01$ | 4.83E-24 | Intestinal mucosa | Treg/Quiescent |  |
| ST8SIA1 | $8.56 \mathrm{E}-01$ | 1.68E-22 | Intestinal mucosa | Treg/Quiescent |  |
| RPL13P12 | $2.96 \mathrm{E}-01$ | 2.98E-20 | Intestinal mucosa | Treg/Quiescent |  |
| ACTB | $3.58 \mathrm{E}-01$ | 2.90E-19 | Intestinal mucosa | Treg/Quiescent |  |
| TIGIT | 7.33E-01 | 2.18E-18 | Intestinal mucosa | Treg/Quiescent |  |
| PDCD1 | 7.20E-01 | 5.88E-17 | Intestinal mucosa | Treg/Quiescent |  |
| CTLA4 | 6.18E-01 | $1.73 \mathrm{E}-16$ | Intestinal mucosa | Treg/Quiescent |  |
| TOX2 | $4.45 \mathrm{E}-01$ | 3.35E-14 | Intestinal mucosa | Treg/Quiescent | - |
| TRPS1 | $1.11 \mathrm{E}+00$ | 6.72E-13 | Intestinal mucosa | Treg/Quiescent | - |
| KIAA1551 | $6.39 \mathrm{E}-01$ | 8.18E-13 | Intestinal mucosa | Treg/Quiescent |  |
| IL6ST | $7.54 \mathrm{E}-01$ | 1.62E-12 | Intestinal mucosa | Treg/Quiescent | * |
| CTD.2031P19.5 | $6.75 \mathrm{E}-01$ | 1.80E-11 | Intestinal mucosa | Treg/Quiescent |  |
| DPP7 | $4.42 \mathrm{E}-01$ | 1.13E-10 | Intestinal mucosa | Treg/Quiescent |  |
| MAF | $5.92 \mathrm{E}-01$ | 7.40E-10 | Intestinal mucosa | Treg/Quiescent | - |
| RP11.157G21.2 | $4.63 \mathrm{E}-01$ | 7.70E-10 | Intestinal mucosa | Treg/Quiescent |  |
| CHRM3.AS2 | $5.49 \mathrm{E}-01$ | 2.58E-09 | Intestinal mucosa | Treg/Quiescent |  |
| CD38 | $4.19 \mathrm{E}-01$ | 2.66E-09 | Intestinal mucosa | Treg/Quiescent |  |
| RBM6 | $4.69 \mathrm{E}-01$ | 3.13E-09 | Intestinal mucosa | Treg/Quiescent | - |
| RNU4.2 | $3.23 \mathrm{E}-01$ | 7.10E-09 | Intestinal mucosa | Treg/Quiescent |  |
| TBC1D4 | $6.45 \mathrm{E}-01$ | 3.48E-08 | Intestinal mucosa | Treg/Quiescent |  |
| HNRNPD | 6.03E-01 | 3.89E-08 | Intestinal mucosa | Treg/Quiescent |  |
| SDR39U1 | $4.53 \mathrm{E}-01$ | 4.67E-08 | Intestinal mucosa | Treg/Quiescent |  |
| CNOT6L | 5.03E-01 | 5.65E-08 | Intestinal mucosa | Treg/Quiescent |  |


| Gene | Average log fold change | Adjusted p-value | Compartment | Cell type | Gene annotation |
| :---: | :---: | :---: | :---: | :---: | :---: |
| NFATC1 | $4.20 \mathrm{E}-01$ | 1.32E-07 | Intestinal mucosa | Treg/Quiescent | X |
| HNRNPH3 | $4.94 \mathrm{E}-01$ | 2.12E-07 | Intestinal mucosa | Treg/Quiescent |  |
| FOXP3 | 3.57E-01 | 4.14E-07 | Intestinal mucosa | Treg/Quiescent | - |
| TUBA4A | $3.10 \mathrm{E}-01$ | 6.72E-07 | Intestinal mucosa | Treg/Quiescent |  |
| PLK3 | $3.52 \mathrm{E}-01$ | 1.85E-06 | Intestinal mucosa | Treg/Quiescent |  |
| SIRPG | 4.06E-01 | 2.96E-06 | Intestinal mucosa | Treg/Quiescent |  |
| TOX | $4.11 \mathrm{E}-01$ | 3.82E-06 | Intestinal mucosa | Treg/Quiescent | - |
| EPHB6 | $4.86 \mathrm{E}-01$ | 3.83E-06 | Intestinal mucosa | Treg/Quiescent |  |
| NABP1 | $5.00 \mathrm{E}-01$ | 5.93E-06 | Intestinal mucosa | Treg/Quiescent |  |
| PASK | $5.30 \mathrm{E}-01$ | 6.62E-06 | Intestinal mucosa | Treg/Quiescent |  |
| DGKA | $5.52 \mathrm{E}-01$ | 2.47E-05 | Intestinal mucosa | Treg/Quiescent |  |
| FAN1 | $2.62 \mathrm{E}-01$ | $3.71 \mathrm{E}-05$ | Intestinal mucosa | Treg/Quiescent |  |
| SP110 | 6.01E-01 | 4.94E-05 | Intestinal mucosa | Treg/Quiescent | - |
| CMTM7 | 5.50E-01 | 7.78E-05 | Intestinal mucosa | Treg/Quiescent | * |
| DNPH1 | $4.84 \mathrm{E}-01$ | 8.22E-05 | Intestinal mucosa | Treg/Quiescent |  |
| PTPN7 | $2.52 \mathrm{E}-01$ | 1.03E-04 | Intestinal mucosa | Treg/Quiescent |  |
| ACAD10 | 2.98E-01 | 1.23E-04 | Intestinal mucosa | Treg/Quiescent |  |
| FCMR | $4.05 \mathrm{E}-01$ | 1.81E-04 | Intestinal mucosa | Treg/Quiescent |  |
| CTSB | 4.70E-01 | 7.16E-04 | Intestinal mucosa | Treg/Quiescent |  |
| CDK5R1 | $3.16 \mathrm{E}-01$ | 7.16E-04 | Intestinal mucosa | Treg/Quiescent |  |
| PVT1 | $3.51 \mathrm{E}-01$ | 7.28E-04 | Intestinal mucosa | Treg/Quiescent |  |
| AHI1 | $3.73 \mathrm{E}-01$ | 7.32E-04 | Intestinal mucosa | Treg/Quiescent |  |
| TLK1 | $4.47 \mathrm{E}-01$ | 7.88E-04 | Intestinal mucosa | Treg/Quiescent |  |
| ZNF251 | 3.00E-01 | $9.69 \mathrm{E}-04$ | Intestinal mucosa | Treg/Quiescent | - |
| RNA28S5 | $4.14 \mathrm{E}-01$ | 1.02E-03 | Intestinal mucosa | Treg/Quiescent |  |
| TMEM2 | $3.63 \mathrm{E}-01$ | $1.03 \mathrm{E}-03$ | Intestinal mucosa | Treg/Quiescent |  |
| PTPRCAP | $4.02 \mathrm{E}-01$ | $1.15 \mathrm{E}-03$ | Intestinal mucosa | Treg/Quiescent |  |
| SESN3 | 5.10E-01 | 1.27E-03 | Intestinal mucosa | Treg/Quiescent |  |
| AFTPH | 2.81E-01 | 1.76E-03 | Intestinal mucosa | Treg/Quiescent |  |
| UBA6.AS1 | $2.87 \mathrm{E}-01$ | $1.87 \mathrm{E}-03$ | Intestinal mucosa | Treg/Quiescent |  |
| FYB | $4.33 \mathrm{E}-01$ | 3.79E-03 | Intestinal mucosa | Treg/Quiescent |  |
| TSEN34 | $2.54 \mathrm{E}-01$ | 4.12E-03 | Intestinal mucosa | Treg/Quiescent |  |
| SELENOM | $3.23 \mathrm{E}-01$ | 4.65E-03 | Intestinal mucosa | Treg/Quiescent |  |
| PVALB | $2.96 \mathrm{E}-01$ | 5.27E-03 | Intestinal mucosa | Treg/Quiescent |  |
| RPL10 | $2.50 \mathrm{E}-01$ | 6.18E-03 | Intestinal mucosa | Treg/Quiescent |  |
| MBOAT1 | $2.53 \mathrm{E}-01$ | 8.03E-03 | Intestinal mucosa | Treg/Quiescent |  |
| RPS5 | $3.32 \mathrm{E}-01$ | 1.33E-02 | Intestinal mucosa | Treg/Quiescent |  |
| ZC2HC1A | $3.14 \mathrm{E}-01$ | 2.14E-02 | Intestinal mucosa | Treg/Quiescent |  |
| SYPL1 | $4.76 \mathrm{E}-01$ | 2.24E-02 | Intestinal mucosa | Treg/Quiescent |  |
| STX16 | 2.90E-01 | 2.30E-02 | Intestinal mucosa | Treg/Quiescent |  |

## ACCEPTED MANUSCRIPT

| Gene | Average <br> log fold <br> change | Adjusted <br> p-value | Compartment | Cell type | Gene <br> annotation |
| :--- | :--- | :--- | :--- | :--- | :--- |
| MTATP6P1 | $3.58 \mathrm{E}-01$ | $2.69 \mathrm{E}-02$ | Intestinal mucosa | Treg/Quiescent |  |
| LINC00847 | $3.50 \mathrm{E}-01$ | $2.91 \mathrm{E}-02$ | Intestinal mucosa | Treg/Quiescent |  |
| VWA5A | $2.77 \mathrm{E}-01$ | $3.01 \mathrm{E}-02$ | Intestinal mucosa | Treg/Quiescent |  |
| CD59 | $4.71 \mathrm{E}-01$ | $3.23 \mathrm{E}-02$ | Intestinal mucosa | Treg/Quiescent |  |
| C1orf228 | $2.52 \mathrm{E}-01$ | $3.84 \mathrm{E}-02$ | Intestinal mucosa | Treg/Quiescent |  |

Supplementary Table 2: Specification for materials and resources

|  | Reagent or resource | Source | Identifier/version |
| :---: | :---: | :---: | :---: |
| Antibodies | Anti-Human CD3 APC e780 | eBioscience | 47-0036-42 |
|  | Anti-Human CD8 ${ }^{\text {APC }}$ | Biolegend | 300912 |
|  | Anti-Human CD8 3 APC | BD Biosciences | 641058 |
|  | Anti-Human CD19 APC r700 | BD Biosciences | 564977 |
|  | Anti-Human CD45RO BV421 | BD Biosciences | 562641 |
|  | Anti-Human CD62L PE | Biolegend | 304806 |
|  | Anti-Human CD326 PercpCy5.5 | Biolegend | 324214 |
|  | Anti-Human $\alpha \beta$ TCR FITC | eBioscience | 11-9986-42 |
|  | Propidium iodide | Sigma | 4170 |
|  | Anti-Human REG1A monoclonal antibody | Thermo Fisher Scientific | MA5-15524 |
|  | Anti-Human CD3 polyclonal antibody | Abcam | ab5690 |
| Commercial kits | Nextera XT DNA sample preparation kit | Illumina | FC-131-1096 |
|  | Nextera XT 24-index kit | Illumina | FC-131-1001 |
|  | HT DNA HiSense extended range labchip | PerkinElmer | 760517 |
|  | High output flowcell cartridge v2, 75bp kit. | Illumina | 15065973 |
| Reagents | Lymphoprep solution | STEMCELL | 7801 |
|  | RPMI 1640 (+nil) | Thermo Fisher Scientific | 61870-010 |
|  | HBSS -CMF | Thermo Fisher Scientific | 14175-053 |
|  | EDTA (0.5M) | Sigma-Aldrich | 3690 |
|  | DTT (0.5M) | Thermo Fisher Scientific |  |
|  | Collagenase IV | Sigma | C1889 |
|  | DNAse II type V | Sigma | D8764 |
|  | SUPERase $\bullet \mathrm{In}^{\text {TM }}$ RNase Inhibitor | Thermo Fisher Scientific | AM2696 |
|  | PW1 | Illumina | in Sequencing Kit |
|  | KAPA HiFi HotStart ReadyMix | Sopachem- KAPA Biosystems | KK2601 |
|  | EB solution 10 mM Tris-Cl, pH 8.5 | Qiagen | 19086 |
|  | Ethanol |  |  |



## Supplementary Figure Legends:

Supplementary Figure 1: t-SNE plots representing T cells pooled from three individual patients with Crohn's disease. A) t-SNE plot representing transcriptomes from T cells in peripheral blood (circles) and intestinal mucosa (triangles). B) t-SNE plot representing transcriptomes from intestinal mucosal T cells as depicted in panel A. IEL are presented as circles, LPL as triangles. C) t-SNE plot indicating the presence of surface markers on intestinal mucosal T cells, measured by flow-cytometry, in a binary fashion. D-G) t-SNE plots featuring expression of cellular marker genes in intestinal mucosal T cells. Plots represent gene expression values of a particular gene, measured by single-cell RNA sequencing, ranging from Q0-Q75 of normalized expression values per gene. IEL: intraepithelial T lymphocyte. LPL: lamina propria T lymphocyte. CTL: Cytotoxic T lymphocytes. Quiescent: Quiescent T lymphocytes. REG1A/1B: cells highly expressing REG1A/1B, without expressing Paneth cell markers. Th17: T-helper 17 cells. Effector/Treg: T-regulatory lymphocytes on an effector memory background. Treg/Quiescent: T-regulatory lymphocytes on a quiescent background.



[^0]:    Take-down policy
    If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

